Dr Emmanuel J Favaloro

All Stories

1. 
   Editorial Compilation—Part XVIII

   Article • Seminars in Thrombosis and Hemostasis, January 2026, Thieme Publishing Group

   Dr Emmanuel J Favaloro

2. 
   External quality assessment for unfractionated heparin monitoring: An update from Australasia/Asia-Pacific

   Article • Seminars in Thrombosis and Hemostasis, December 2025, Thieme Publishing Group

   Dr Emmanuel J Favaloro

3. 
   Artificial intelligence and machine learning in thrombosis and hemostasis: a scoping review of clinical and laboratory applications, challenges, and future directions

   Article • Clinical Chemistry and Laboratory Medicine (CCLM), December 2025, De Gruyter

   Dr Emmanuel J Favaloro

4. 
   Welcome to Seminars in Thrombosis and Hemostasis 2026

   Article • Seminars in Thrombosis and Hemostasis, November 2025, Thieme Publishing Group

   Dr Emmanuel J Favaloro

5. 
   Diagnosing thrombophilia: the case for genetic or functional testing?

   Article • Expert Review of Molecular Diagnostics, November 2025, Taylor & Francis

   Dr Emmanuel J Favaloro

6. 
   Red Light Therapy in Thrombosis and Hemostasis

   Article • Seminars in Thrombosis and Hemostasis, October 2025, Thieme Publishing Group

   Dr Emmanuel J Favaloro

7. 
   A contemporary analysis of solid phase antiphospholipid antibody testing: implications for classification or diagnosis of antiphospholipid syndrome

   Article • Pathology, October 2025, Elsevier

   Dr Emmanuel J Favaloro

8. 
   The increasing association of pulmonary embolism with cancer deaths: A seven-year, US-based, nationwide analysis

   Article • Public Health, October 2025, Elsevier

   Dr Emmanuel J Favaloro

9. 
   Sustainable anticoagulation for climate resilient care

   Article • The Lancet Haematology, September 2025, Elsevier

   Dr Emmanuel J Favaloro

10. 
    “Alterations in visible light exposure modulate platelet function and regulate thrombus formation”: comment from Fan et al.

    Article • Journal of Thrombosis and Haemostasis, September 2025, Elsevier

    Dr Emmanuel J Favaloro

11. 
    Overview of laboratory diagnostics for immediate management of patients presenting to the emergency department with acute bleeding

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), August 2025, De Gruyter

    Dr Emmanuel J Favaloro

12. 
    Acquired von Willebrand syndrome in children

    Article • Research and Practice in Thrombosis and Haemostasis, August 2025, Elsevier

    Dr Emmanuel J Favaloro

13. 
    Clinical Significance of APTT Tests and Their Correlation with Heparin Anti-Xa and Anti-IIa Activities is Transformed by Pairing with a Heparin-Resistant Recalcification Solution (HRRS)

    Article • July 2025, MDPI AG

    Dr Emmanuel J Favaloro

14. 
    Seminars in Thrombosis and Hemostasis: 2024 Impact Factor, Most Highly Cited Papers, and Other Journal Metrics

    Article • Seminars in Thrombosis and Hemostasis, July 2025, Thieme Publishing Group

    Dr Emmanuel J Favaloro

15. 
    Lupus Anticoagulant Testing for Diagnosis of Antiphospholipid Syndrome: A Perspective Informed by Local Practice

    Article • Journal of Clinical Medicine, July 2025, MDPI AG

    Dr Emmanuel J Favaloro

16. 
    A Review of Desmopressin Use in Bleeding Disorders: An Unsung Hero?

    Article • Biomolecules, July 2025, MDPI AG

    Dr Emmanuel J Favaloro

17. 
    Editorial Compilation—XVII

    Article • Seminars in Thrombosis and Hemostasis, June 2025, Thieme Publishing Group

    Dr Emmanuel J Favaloro

18. 
    Hemolysis detection accuracy on Stago sthemO 301

    Article • Blood Coagulation & Fibrinolysis, May 2025, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

19. 
    An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: guidance from the ISTH-SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies: reply

    Article • Journal of Thrombosis and Haemostasis, May 2025, Elsevier

    Dr Emmanuel J Favaloro

20. 
    2024 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards

    Article • Seminars in Thrombosis and Hemostasis, April 2025, Thieme Publishing Group

    Dr Emmanuel J Favaloro

21. 
    Oral Anticoagulation Therapy: An Update on Usage and Costs in the Endemic COVID-19 Era

    Article • Journal of Clinical Medicine, April 2025, MDPI AG

    Dr Emmanuel J Favaloro

22. 
    Comparative evaluation of routine coagulation testing on Stago sthemO 301 and Werfen ACL TOP 750

    Article • Diagnosis, April 2025, De Gruyter

    Dr Emmanuel J Favaloro

23. 
    Mortality from Pulmonary Embolism in Patients with Post-Coronavirus Disease Syndrome

    Article • Seminars in Thrombosis and Hemostasis, March 2025, Thieme Publishing Group

    Dr Emmanuel J Favaloro

24. 
    2025 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

    Article • Seminars in Thrombosis and Hemostasis, March 2025, Thieme Publishing Group

    Dr Emmanuel J Favaloro

25. 
    Nebulized Heparin in 2025: at the Interface between Promising Benefits and the Need for Further Research

    Article • Seminars in Thrombosis and Hemostasis, March 2025, Thieme Publishing Group

    Dr Emmanuel J Favaloro

26. 
    Factor Inhibitor Testing: An Update from Australasia/Asia-Pacific

    Article • Seminars in Thrombosis and Hemostasis, February 2025, Thieme Publishing Group

    Dr Emmanuel J Favaloro

27. 
    Manual tilt tube method for prothrombin time: a commentary on contemporary relevance

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), February 2025, De Gruyter

    Dr Emmanuel J Favaloro

28. 
    Activated Protein C Resistance Testing: An Update From Australasia/Asia‐Pacific

    Article • International Journal of Laboratory Hematology, February 2025, Wiley

    Dr Emmanuel J Favaloro

29. 
    From errors to excellence: the pre-analytical journey to improved quality in diagnostics. A scoping review

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2025, De Gruyter

    Dr Emmanuel J Favaloro

30. 
    Laboratory Assessment of Factor VIII Inhibitors: When Is It Required? A Perspective Informed by Local Practice

    Article • Journal of Clinical Medicine, December 2024, MDPI AG

    Dr Emmanuel J Favaloro

31. 
    Current and emerging therapies as potential treatment for people with von Willebrand disease

    Article • Expert Review of Hematology, November 2024, Taylor & Francis

    Dr Emmanuel J Favaloro

32. 
    Innovative Diagnostic Solutions in Hemostasis

    Article • Diagnostics, November 2024, MDPI AG

    Dr Emmanuel J Favaloro

33. 
    Sticky Platelet Syndrome Revisited?

    Article • Seminars in Thrombosis and Hemostasis, November 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

34. 
    An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: guidance from the ISTH-SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies

    Article • Journal of Thrombosis and Haemostasis, November 2024, Elsevier

    Dr Emmanuel J Favaloro

35. 
    Laboratory Testing for ADAMTS13 for Thrombotic Thrombocytopenia Purpura and Beyond

    Article • Seminars in Thrombosis and Hemostasis, October 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

36. 
    Welcome to Seminars in Thrombosis and Hemostasis 2025: Toward the Next 50 Years of Publishing and Announcement of New Online Manuscript Submission System

    Article • Seminars in Thrombosis and Hemostasis, October 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

37. 
    Innovative Diagnostic Solutions in Hemostasis

    Article • October 2024, MDPI AG

    Dr Emmanuel J Favaloro

38. 
    Reflections on World Thrombosis Day 2024

    Article • Thrombosis and Haemostasis, October 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

39. 
    Revisiting the Environmental Impact of Inappropriate Clinical Laboratory Testing: A Comprehensive Overview of Sustainability, Economic, and Quality of Care Outcomes

    Article • The Journal of Applied Laboratory Medicine, October 2024, Oxford University Press (OUP)

    Dr Emmanuel J Favaloro

40. 
    Reliability of generative artificial intelligence in identifying the major risk factors for venous thrombosis

    Article • Blood Coagulation & Fibrinolysis, October 2024, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

41. 
    Routine Coagulation

    Article • Clinics in Laboratory Medicine, September 2024, Elsevier

    Dr Emmanuel J Favaloro

42. 
    Erratum: Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus Paper

    Article • Thrombosis and Haemostasis, August 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

43. 
    Heparin and Posttraumatic Stress Disorder

    Article • Seminars in Thrombosis and Hemostasis, July 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

44. 
    New STH 2023 Impact Factor, Most Highly Cited Papers, and Other Journal Metrics

    Article • Seminars in Thrombosis and Hemostasis, July 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

45. 
    Continued harmonization of the international normalized ratio across a large laboratory network: Evidence of sustained low interlaboratory variation and bias after a change in instrumentation

    Article • American Journal of Clinical Pathology, July 2024, Oxford University Press (OUP)

    Dr Emmanuel J Favaloro

46. 
    EFLM Task Force Preparation of Labs for Emergencies (TF-PLE) recommendations for reinforcing cyber-security and managing cyber-attacks in medical laboratories

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), July 2024, De Gruyter

    Dr Emmanuel J Favaloro

47. 
    EFLM Task Force Preparation of Labs for Emergencies (TF-PLE) survey on cybersecurity

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), July 2024, De Gruyter

    Dr Emmanuel J Favaloro

48. 
    2023 Eberhard F. Mammen Award Announcements: Part II–Young Investigator Awards

    Article • Seminars in Thrombosis and Hemostasis, July 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

49. 
    COVID-19 vaccination prevents venous thrombosis in patients with SARS-CoV-2 infection and thereafter

    Article • Blood Coagulation & Fibrinolysis, July 2024, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

50. 
    The Role of Viscoelastic Testing in Assessing Hemostasis: A Challenge to Standard Laboratory Assays?

    Article • Journal of Clinical Medicine, June 2024, MDPI AG

    Dr Emmanuel J Favaloro

51. 
    Should APTT become part of thrombophilia screening?

    Article • Diagnosis, May 2024, De Gruyter

    Dr Emmanuel J Favaloro

52. 
    Contact Activation: Where Thrombosis and Hemostasis Meet on a Foreign Surface, Plus a Mini-editorial Compilation (“Part XVI”)

    Article • Seminars in Thrombosis and Hemostasis, May 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

53. 
    Prone Position and the Risk of Venous Thrombosis in COVID-19 Patients with Respiratory Failure

    Article • Seminars in Thrombosis and Hemostasis, May 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

54. 
    Performance of direct oral anticoagulant (DOAC) testing by hemostasis laboratories: The Australasian/Asia‐Pacific experience

    Article • International Journal of Laboratory Hematology, April 2024, Wiley

    Dr Emmanuel J Favaloro

55. 
    The Most Highly Downloaded Publications from Seminars in Thrombosis and Hemostasis: A Data Analysis 10 Years in the Making

    Article • Seminars in Thrombosis and Hemostasis, April 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

56. 
    Celebrating 50 Years of Seminars in Thrombosis and Hemostasis—Part IV

    Article • Seminars in Thrombosis and Hemostasis, April 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

57. 
    Laboratory diagnosis of von Willebrand disease: the phenotype

    Article • March 2024, Wiley

    Dr Emmanuel J Favaloro

58. 
    Editorial Compilation—XV

    Article • Seminars in Thrombosis and Hemostasis, March 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

59. 
    2024 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

    Article • Seminars in Thrombosis and Hemostasis, March 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

60. 
    Pearls and Pitfalls in the Measurement of Direct Oral Anticoagulants

    Article • Seminars in Thrombosis and Hemostasis, March 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

61. 
    Variable Performance of D-dimer Testing by Hemostasis Laboratories: The Australasian/Asia-Pacific Experience

    Article • Seminars in Thrombosis and Hemostasis, March 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

62. 
    D-dimer Levels for the exclusion of pulmonary embolism: making sense of international guideline recommendations

    Article • Journal of Thrombosis and Haemostasis, March 2024, Elsevier

    Dr Emmanuel J Favaloro

63. 
    Testing for the lupus anticoagulant: the good, the bad, and the ugly

    Article • Research and Practice in Thrombosis and Haemostasis, March 2024, Elsevier

    Dr Emmanuel J Favaloro

64. 
    Venous Thrombosis in Airborne Viral Infections: Is Coronavirus Disease 2019 now Any Different from Influenza?

    Article • Seminars in Thrombosis and Hemostasis, February 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

65. 
    Diagnostic value of D-dimer in differentiating multisystem inflammatory syndrome in Children (MIS-C) from Kawasaki disease: systematic literature review and meta-analysis

    Article • Diagnosis, February 2024, De Gruyter

    Dr Emmanuel J Favaloro

66. 
    Unfractionated heparin: optimizing laboratory monitoring and reducing unwanted interference in everyday hemostasis test practice

    Article • Polish Archives of Internal Medicine, February 2024, Towarzystwo Internistow Polskich/Polish Society of Internal Medicine

    Dr Emmanuel J Favaloro

67. 
    Simplified Method for Removing Direct Oral Anticoagulant Interference in Mechanical Coagulation Test Systems—A Proof of Concept

    Article • Journal of Clinical Medicine, February 2024, MDPI AG

    Dr Emmanuel J Favaloro

68. 
    Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus Paper

    Article • Thrombosis and Haemostasis, February 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

69. 
    Therapeutic drug monitoring of selected direct oral anticoagulants

    Article • January 2024, Elsevier

    Dr Emmanuel J Favaloro

70. 
    Artificial intelligence in the pre-analytical phase: State-of-the art and future perspectives

    Article • Journal of Medical Biochemistry, January 2024, Centre for Evaluation in Education and Science (CEON/CEES)

    Dr Emmanuel J Favaloro

71. 
    D-dimer diagnostics: can I use any D-dimer assay? Bridging the knowledge-to-action gap

    Article • Research and Practice in Thrombosis and Haemostasis, January 2024, Elsevier

    Dr Emmanuel J Favaloro

72. 
    Recent monthly mortality for pulmonary embolism in the US

    Article • Thrombosis Research, January 2024, Elsevier

    Dr Emmanuel J Favaloro

73. 
    Vaccine-induced (immune) thrombotic thrombocytopenia (VITT): Diagnosis, guidelines, and reporting

    Article • January 2024, Elsevier

    Dr Emmanuel J Favaloro

74. 
    von Willebrand Disease

    Article • January 2024, Elsevier

    Dr Emmanuel J Favaloro

75. 
    Variable Performance of Lupus Anticoagulant Testing: The Australasian/Asia-Pacific Experience

    Article • Seminars in Thrombosis and Hemostasis, November 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

76. 
    Description of an In Vitro Platelet Function Analyzer (PFA-100/PFA-200) 30 Years in the Making

    Article • Seminars in Thrombosis and Hemostasis, October 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

77. 
    Classification Criteria for the Antiphospholipid Syndrome: Not the Same as Diagnostic Criteria for Antiphospholipid Syndrome

    Article • Seminars in Thrombosis and Hemostasis, October 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

78. 
    The Most Highly Cited Publications from Seminars in Thrombosis and Hemostasis: A Data Analysis 50 Years in the Making

    Article • Seminars in Thrombosis and Hemostasis, September 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

79. 
    Editorial Compilation XIV

    Article • Seminars in Thrombosis and Hemostasis, September 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

80. 
    Effect of syringe underfilling on the quality of venous blood gas analysis

    Article • Diagnosis, September 2023, De Gruyter

    Dr Emmanuel J Favaloro

81. 
    Celebrating 50 Years of Seminars in Thrombosis and Hemostasis—Part III

    Article • Seminars in Thrombosis and Hemostasis, August 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

82. 
    Welcome to Seminars in Thrombosis and Hemostasis 2024: 50 Years of Publishing

    Article • Seminars in Thrombosis and Hemostasis, August 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

83. 
    New Seminars in Thrombosis and Hemostasis 2022 Impact Factor, Most Highly Cited Papers, and Other Journal Metrics

    Article • Seminars in Thrombosis and Hemostasis, August 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

84. 
    Are Antiphospholipid Antibodies a Surrogate Risk Factor for Thrombosis in Sepsis?

    Article • Seminars in Thrombosis and Hemostasis, July 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

85. 
    Incomplete filling of spray-dried K2EDTA evacuated blood tubes: impact on measuring routine hematological parameters on Sysmex XN-10

    Article • Diagnosis, July 2023, De Gruyter

    Dr Emmanuel J Favaloro

86. 
    Comparison of 2 ways of performing ristocetin-induced platelet agglutination mixing study for diagnosis of type 2B von Willebrand disease. Response to the publication of Soleimani et al

    Article • Research and Practice in Thrombosis and Haemostasis, July 2023, Elsevier

    Dr Emmanuel J Favaloro

87. 
    Laboratory diagnosis of von Willebrand disease in the age of the new guidelines: considerations based on geography and resources

    Article • Research and Practice in Thrombosis and Haemostasis, July 2023, Elsevier

    Dr Emmanuel J Favaloro

88. 
    Letter in response to Colpani et al “A comparative study in type 2 von Willebrand disease patients using four different platelet-dependent von Willebrand factor assays”

    Article • Research and Practice in Thrombosis and Haemostasis, July 2023, Elsevier

    Dr Emmanuel J Favaloro

89. 
    Results of the first survey of the EFLM Task Force Preparation of Labs for Emergencies (TF-PLE)

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), June 2023, De Gruyter

    Dr Emmanuel J Favaloro

90. 
    Disruption of Laboratory Activities during the COVID-19 Pandemic: Results of an EFLM Task Force Preparation of Labs for Emergencies (TF-PLE) Survey

    Article • June 2023, MDPI AG

    Dr Emmanuel J Favaloro

91. 
    Epidemiology and Predisposing Factors of Post-COVID Venous Thrombosis: A Concise Review

    Article • Seminars in Thrombosis and Hemostasis, June 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

92. 
    Effects of Recombinant SARS-CoV-2 Spike Protein Variants on Platelet Morphology and Activation

    Article • Seminars in Thrombosis and Hemostasis, June 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

93. 
    Incomplete filling of spray-dried K2EDTA evacuated blood tubes: impact on measuring routine hematological parameters on Sysmex XN-10

    Article • June 2023, Research Square

    Dr Emmanuel J Favaloro

94. 
    Illustrated State-of-the-Art Capsules of the ISTH 2023 Congress

    Article • Research and Practice in Thrombosis and Haemostasis, May 2023, Elsevier

    Dr Emmanuel J Favaloro

95. 
    2022 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards

    Article • Seminars in Thrombosis and Hemostasis, April 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

96. 
    A multicenter evaluation of the Technoscreen ADAMTS13 activity semi‐quantitative screening test for thrombotic thrombocytopenic purpura diagnosis and exclusion

    Article • International Journal of Laboratory Hematology, April 2023, Wiley

    Dr Emmanuel J Favaloro

97. 
    Reducing our carbon footprint in the haematology laboratory: A shared responsibility

    Article • International Journal of Laboratory Hematology, March 2023, Wiley

    Dr Emmanuel J Favaloro

98. 
    2023 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

    Article • Seminars in Thrombosis and Hemostasis, March 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

99. 
    To Clot or Not to Clot: Is That the Question?

    Article • Journal of Clinical Medicine, March 2023, MDPI AG

    Dr Emmanuel J Favaloro

100. 
     Platelet-activating functional assay resolution in vaccine-induced immune thrombotic thrombocytopenia: differential alignment to PF4 ELISA platforms

     Article • Research and Practice in Thrombosis and Haemostasis, March 2023, Elsevier

     Dr Emmanuel J Favaloro

101. 
     Mixing factor Xa and thrombin inhibiting direct oral anticoagulants produces a synergistic prolonging effect on most clotting tests

     Article • International Journal of Laboratory Hematology, February 2023, Wiley

     Dr Emmanuel J Favaloro

102. 
     The Role of the von Willebrand Factor Collagen-Binding Assay (VWF:CB) in the Diagnosis and Treatment of von Willebrand Disease (VWD) and Way Beyond: A Comprehensive 36-Year History

     Article • Seminars in Thrombosis and Hemostasis, February 2023, Thieme Publishing Group

     Dr Emmanuel J Favaloro

103. 
     Editorial Compilation—XIII

     Article • Seminars in Thrombosis and Hemostasis, February 2023, Thieme Publishing Group

     Dr Emmanuel J Favaloro

104. 
     Evolution of Hemostasis Testing: A Personal Reflection Covering over 40 Years of History*

     Article • Seminars in Thrombosis and Hemostasis, February 2023, Thieme Publishing Group

     Dr Emmanuel J Favaloro

105. 
     Pathology utilisation during COVID-19 outbreaks beyond viral testing: routine coagulation and D-dimer testing

     Article • Pathology, February 2023, Elsevier

     Dr Emmanuel J Favaloro

106. 
     Mechanisms of Thrombosis in Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia

     Article • Seminars in Thrombosis and Hemostasis, January 2023, Thieme Publishing Group

     Dr Emmanuel J Favaloro

107. 
     Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19)—Part IV

     Article • Seminars in Thrombosis and Hemostasis, January 2023, Thieme Publishing Group

     Dr Emmanuel J Favaloro

108. 
     Welcome to Seminars in Thrombosis & Hemostasis 2023

     Article • Seminars in Thrombosis and Hemostasis, January 2023, Thieme Publishing Group

     Dr Emmanuel J Favaloro

109. 
     Application of anti-Xa assay in monitoring unfractionated heparin therapy in contemporary antithrombotic management

     Article • Expert Review of Hematology, January 2023, Taylor & Francis

     Dr Emmanuel J Favaloro

110. 
     von Willebrand Disease: An Update on Diagnosis and Treatment

     Article • January 2023, Springer Science + Business Media

     Dr Emmanuel J Favaloro

111. 
     An Overview of Laboratory Testing for ADAMTS13

     Article • January 2023, Springer Science + Business Media

     Dr Emmanuel J Favaloro

112. 
     An Overview of Laboratory Testing for Antiphospholipid Antibodies

     Article • January 2023, Springer Science + Business Media

     Dr Emmanuel J Favaloro

113. 
     Antiphospholipid Antibody Testing for Anti-cardiolipin and Anti-β2 Glycoprotein I Antibodies Using Chemiluminescence-Based Panels

     Article • January 2023, Springer Science + Business Media

     Dr Emmanuel J Favaloro

114. 
     Auto-validation of Routine Coagulation/Hemostasis Assays with Reflex Testing of Abnormal Test Results

     Article • January 2023, Springer Science + Business Media

     Dr Emmanuel J Favaloro

115. 
     Automated and Rapid ADAMTS13 Testing Using Chemiluminescence: Utility for Identification or Exclusion of TTP and Beyond

     Article • January 2023, Springer Science + Business Media

     Dr Emmanuel J Favaloro

116. 
     Harmonization of Hemostasis Testing Across a Large Laboratory Network: An Example from Australia

     Article • January 2023, Springer Science + Business Media

     Dr Emmanuel J Favaloro

117. 
     Hemostasis and Thrombosis: An Overview Focusing on Associated Laboratory Testing to Diagnose and Help Manage Related Disorders

     Article • January 2023, Springer Science + Business Media

     Dr Emmanuel J Favaloro

118. 
     Heparin-Induced Thrombotic Thrombocytopenia (HITT) and Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): Similar but Different

     Article • January 2023, Springer Science + Business Media

     Dr Emmanuel J Favaloro

119. 
     Identification of ADAMTS13 Inhibitors in Acquired TTP

     Article • January 2023, Springer Science + Business Media

     Dr Emmanuel J Favaloro

120. 
     Laboratory Testing for Activated Protein C Resistance (APCR): An Update

     Article • January 2023, Springer Science + Business Media

     Dr Emmanuel J Favaloro

121. 
     Laboratory Testing for von Willebrand Disease Using a Composite Rapid 3-Test Chemiluminescence-Based von Willebrand Factor Assay Panel

     Article • January 2023, Springer Science + Business Media

     Dr Emmanuel J Favaloro

122. 
     Laboratory Testing for von Willebrand Factor: Factor VIII Binding for the Diagnosis or Exclusion of Type 2N von Willebrand Disease: An Update

     Article • January 2023, Springer Science + Business Media

     Dr Emmanuel J Favaloro

123. 
     Post-analytical Issues in Hemostasis and Thrombosis Testing: An Update

     Article • January 2023, Springer Science + Business Media

     Dr Emmanuel J Favaloro

124. 
     Celebrating 50 Years of Seminars in Thrombosis and Hemostasis—Part II

     Article • Seminars in Thrombosis and Hemostasis, December 2022, Thieme Publishing Group

     Dr Emmanuel J Favaloro

125. 
     Assessment of immunological anti‐platelet factor 4 antibodies for vaccine‐induced thrombotic thrombocytopenia (VITT) in a large Australian cohort: A multicenter study comprising 1284 patients

     Article • Journal of Thrombosis and Haemostasis, December 2022, Elsevier

     Dr Emmanuel J Favaloro

126. 
     Corrigendum to “A multicentre assessment of contemporary laboratory assays for heparin induced thrombocytopenia” [Pathology (53) (2021) 247–256]

     Article • Pathology, December 2022, Elsevier

     Dr Emmanuel J Favaloro

127. 
     How often are parenteral anticoagulants administered by parents?

     Article • Journal of Thrombosis and Haemostasis, December 2022, Elsevier

     Dr Emmanuel J Favaloro

128. 
     Autoimmune Diseases Affecting Hemostasis: A Narrative Review

     Article • International Journal of Molecular Sciences, November 2022, MDPI AG

     Dr Emmanuel J Favaloro

129. 
     Dedication to Santa Maria Favaloro (1926–2022)

     Article • Seminars in Thrombosis and Hemostasis, November 2022, Thieme Publishing Group

     Dr Emmanuel J Favaloro

130. 
     The myths behind DOAC measurement: Analyses of prescribing information from different regulatory bodies and a call for harmonization

     Article • Journal of Thrombosis and Haemostasis, November 2022, Elsevier

     Dr Emmanuel J Favaloro

131. 
     Letter to the Editor: 10-Year Evolution in Worldwide Usage of Anticoagulant Drugs

     Article • Seminars in Thrombosis and Hemostasis, September 2022, Thieme Publishing Group

     Dr Emmanuel J Favaloro

132. 
     Toward 50 Years of Seminars in Thrombosis and Hemostasis

     Article • Seminars in Thrombosis and Hemostasis, September 2022, Thieme Publishing Group

     Dr Emmanuel J Favaloro

133. 
     Celebrating 50 Years of Seminars in Thrombosis and Hemostasis—Part I

     Article • Seminars in Thrombosis and Hemostasis, September 2022, Thieme Publishing Group

     Dr Emmanuel J Favaloro

134. 
     Strength of Anticoagulation in Moderate to Severe COVID-19 Illness: In Medio Stat Virtus?

     Article • Seminars in Thrombosis and Hemostasis, September 2022, Thieme Publishing Group

     Dr Emmanuel J Favaloro

135. 
     New Seminars in Thrombosis and Hemostasis (STH) 2021 Impact Factor, Most Highly Cited Papers, and Other Journal Metrics

     Article • Seminars in Thrombosis and Hemostasis, September 2022, Thieme Publishing Group

     Dr Emmanuel J Favaloro

136. 
     Laboratory Diagnosis of von Willebrand Disease (VWD): Geographical Perspectives

     Article • Seminars in Thrombosis and Hemostasis, September 2022, Thieme Publishing Group

     Dr Emmanuel J Favaloro

137. 
     Harmonizing factor assay-related testing performed in a large laboratory network

     Article • Blood Coagulation & Fibrinolysis, July 2022, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

138. 
     Towards 50 years of platelet function analyser (PFA) testing

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), July 2022, De Gruyter

     Dr Emmanuel J Favaloro

139. 
     D-dimer: old dogmas, new (COVID-19) tricks

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), July 2022, De Gruyter

     Dr Emmanuel J Favaloro

140. 
     A Review of Autoimmune Acquired von Willebrand Factor Deficiency in Japan

     Article • Seminars in Thrombosis and Hemostasis, July 2022, Thieme Publishing Group

     Dr Emmanuel J Favaloro

141. 
     D-dimers—“Normal” Levels versus Elevated Levels Due to a Range of Conditions, Including “D-dimeritis,” Inflammation, Thromboembolism, Disseminated Intravascular Coagulation, and COVID-19

     Article • Seminars in Thrombosis and Hemostasis, July 2022, Thieme Publishing Group

     Dr Emmanuel J Favaloro

142. 
     Evaluating Performance of Contemporary and Historical von Willebrand Factor (VWF) Assays in the Laboratory Identification of von Willebrand Disease (VWD): The Australasian Experience

     Article • Seminars in Thrombosis and Hemostasis, July 2022, Thieme Publishing Group

     Dr Emmanuel J Favaloro

143. 
     Editorial Compilation XII

     Article • Seminars in Thrombosis and Hemostasis, July 2022, Thieme Publishing Group

     Dr Emmanuel J Favaloro

144. 
     Counting the carbon cost of heparin: an evolving tragedy of the commons?

     Article • The Lancet Haematology, July 2022, Elsevier

     Dr Emmanuel J Favaloro

145. 
     Getting smart with coagulation

     Article • Journal of Thrombosis and Haemostasis, July 2022, Elsevier

     Dr Emmanuel J Favaloro

146. 
     Harmonizing platelet function analyzer testing and reporting in a large laboratory network

     Article • International Journal of Laboratory Hematology, June 2022, Wiley

     Dr Emmanuel J Favaloro

147. 
     Heparin: The Journey from Parenteral Agent to Nasal Delivery

     Article • Seminars in Thrombosis and Hemostasis, June 2022, Thieme Publishing Group

     Dr Emmanuel J Favaloro

148. 
     2022 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

     Article • Seminars in Thrombosis and Hemostasis, June 2022, Thieme Publishing Group

     Dr Emmanuel J Favaloro

149. 
     A novel flow cytometry procoagulant assay for diagnosis of vaccine-induced immune thrombotic thrombocytopenia

     Article • Blood Advances, June 2022, American Society of Hematology

     Dr Emmanuel J Favaloro

150. 
     Complement Levels at Admission Reflecting Progression to Severe Acute Kidney Injury (AKI) in Coronavirus Disease 2019 (COVID-19): A Multicenter Prospective Cohort Study

     Article • Frontiers in Medicine, April 2022, Frontiers

     Dr Emmanuel J Favaloro

151. 
     Cell-Free DNA, Neutrophil extracellular traps (NETs), and Endothelial Injury in Coronavirus Disease 2019– (COVID-19–) Associated Acute Kidney Injury

     Article • Mediators of Inflammation, April 2022, Hindawi Publishing Corporation

     Dr Emmanuel J Favaloro

152. 
     “Von Willebrand disease type 2M: Correlation between genotype and phenotype”: Comment from Favaloro

     Article • Journal of Thrombosis and Haemostasis, April 2022, Elsevier

     Dr Emmanuel J Favaloro

153. 
     2021 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards

     Article • Seminars in Thrombosis and Hemostasis, April 2022, Thieme Publishing Group

     Dr Emmanuel J Favaloro

154. 
     Evaluating errors in the laboratory identification of von Willebrand disease using contemporary von Willebrand factor assays

     Article • Pathology, April 2022, Elsevier

     Dr Emmanuel J Favaloro

155. 
     Laboratory testing for platelet factor 4 antibodies: differential utility for diagnosis/exclusion of heparin induced thrombocytopenia versus suspected vaccine induced thrombotic thrombocytopenia

     Article • Pathology, April 2022, Elsevier

     Dr Emmanuel J Favaloro

156. 
     Measurement of procoagulant platelets provides mechanistic insight and diagnostic potential in heparin‐induced thrombocytopenia

     Article • Journal of Thrombosis and Haemostasis, April 2022, Elsevier

     Dr Emmanuel J Favaloro

157. 
     The Intriguing Connections between von Willebrand Factor, ADAMTS13 and Cancer

     Article • Healthcare, March 2022, MDPI AG

     Dr Emmanuel J Favaloro

158. 
     A multi‐laboratory assessment of lupus anticoagulant assays performed on the ACL TOP 50 family for harmonized testing in a large laboratory network

     Article • International Journal of Laboratory Hematology, March 2022, Wiley

     Dr Emmanuel J Favaloro

159. 
     Editorial Compilation XI

     Article • Seminars in Thrombosis and Hemostasis, February 2022, Thieme Publishing Group

     Dr Emmanuel J Favaloro

160. 
     The Benefits of Heparin Use in COVID-19: Pleiotropic Antiviral Activity beyond Anticoagulant and Anti-Inflammatory Properties

     Article • Seminars in Thrombosis and Hemostasis, February 2022, Thieme Publishing Group

     Dr Emmanuel J Favaloro

161. 
     An Analysis of the Sensitivity of the Activated Partial Thromboplastin Time (APTT) Assay, as Used in a Large Laboratory Network, to Coagulation Factor Deficiencies

     Article • American Journal of Clinical Pathology, February 2022, Oxford University Press (OUP)

     Dr Emmanuel J Favaloro

162. 
     Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19)—Part III

     Article • Seminars in Thrombosis and Hemostasis, February 2022, Thieme Publishing Group

     Dr Emmanuel J Favaloro

163. 
     Welcome to Seminars in Thrombosis & Hemostasis 2022

     Article • Seminars in Thrombosis and Hemostasis, February 2022, Thieme Publishing Group

     Dr Emmanuel J Favaloro

164. 
     Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants

     Article • Research and Practice in Thrombosis and Haemostasis, February 2022, Elsevier

     Dr Emmanuel J Favaloro

165. 
     Should multiple factor dilutions be performed for all patient coagulation factor assays? Let the debate begin!

     Article • Research and Practice in Thrombosis and Haemostasis, February 2022, Elsevier

     Dr Emmanuel J Favaloro

166. 
     Comparing the quality of testing for von Willebrand disease in different geographic localities

     Article • Haemophilia, January 2022, Wiley

     Dr Emmanuel J Favaloro

167. 
     Antibodies against Platelet Factor 4 and Their Associated Pathologies: From HIT/HITT to Spontaneous HIT-Like Syndrome, to COVID-19, to VITT/TTS

     Article • Antibodies, January 2022, MDPI AG

     Dr Emmanuel J Favaloro

168. 
     Commentary on the ASH ISTH NHF WFH 2021 guidelines on the diagnosis of VWD: reflections based on recent contemporary test data

     Article • Blood Advances, January 2022, American Society of Hematology

     Dr Emmanuel J Favaloro

169. 
     What We Know (and Do not Know) Regarding the Pathogenesis of Pulmonary Thrombosis in COVID-19

     Article • Seminars in Thrombosis and Hemostasis, January 2022, Thieme Publishing Group

     Dr Emmanuel J Favaloro

170. 
     2B von Willebrand disease diagnosis: Considerations reflecting on 2021 multisociety guidelines

     Article • Research and Practice in Thrombosis and Haemostasis, December 2021, Elsevier

     Dr Emmanuel J Favaloro

171. 
     Review and evolution of guidelines for diagnosis of COVID-19 vaccine induced thrombotic thrombocytopenia (VITT)

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), November 2021, De Gruyter

     Dr Emmanuel J Favaloro

172. 
     Guidance on the critical shortage of sodium citrate coagulation tubes for hemostasis testing

     Article • Journal of Thrombosis and Haemostasis, November 2021, Elsevier

     Dr Emmanuel J Favaloro

173. 
     The role of lipoprotein(a) in coronavirus disease 2019 (COVID-19) with relation to development of severe acute kidney injury

     Article • Journal of Thrombosis and Thrombolysis, October 2021, Springer Science + Business Media

     Dr Emmanuel J Favaloro

174. 
     Cerebral Venous Thrombosis Developing after COVID-19 Vaccination: VITT, VATT, TTS, and More

     Article • Seminars in Thrombosis and Hemostasis, October 2021, Thieme Publishing Group

     Dr Emmanuel J Favaloro

175. 
     Editorial Compilation X

     Article • Seminars in Thrombosis and Hemostasis, October 2021, Thieme Publishing Group

     Dr Emmanuel J Favaloro

176. 
     New STH (2020) Impact Factor, Most Highly Cited Papers, and Other Journal Metrics

     Article • Seminars in Thrombosis and Hemostasis, October 2021, Thieme Publishing Group

     Dr Emmanuel J Favaloro

177. 
     The Intriguing Relationships of von Willebrand Factor, ADAMTS13 and Cardiac Disease

     Article • Journal of Cardiovascular Development and Disease, September 2021, MDPI AG

     Dr Emmanuel J Favaloro

178. 
     Why is Misdiagnosis of von Willebrand Disease Still Prevalent and How Can We Overcome It? A Focus on Clinical Considerations and Recommendations

     Article • Journal of Blood Medicine, August 2021, Taylor & Francis

     Dr Emmanuel J Favaloro

179. 
     Harmonized D-dimer levels upon admission for prognosis of COVID-19 severity: Results from a Spanish multicenter registry (BIOCOVID-Spain study)

     Article • Journal of Thrombosis and Thrombolysis, July 2021, Springer Science + Business Media

     Dr Emmanuel J Favaloro

180. 
     Laboratory testing for suspected COVID‐19 vaccine–induced (immune) thrombotic thrombocytopenia

     Article • International Journal of Laboratory Hematology, June 2021, Wiley

     Dr Emmanuel J Favaloro

181. 
     COVID-19 and Antiphospholipid Antibodies: Time for a Reality Check?

     Article • Seminars in Thrombosis and Hemostasis, June 2021, Thieme Publishing Group

     Dr Emmanuel J Favaloro

182. 
     Is Lupus Anticoagulant a Significant Feature of COVID-19? A Critical Appraisal of the Literature

     Article • Seminars in Thrombosis and Hemostasis, June 2021, Thieme Publishing Group

     Dr Emmanuel J Favaloro

183. 
     Elevated soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patients

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), June 2021, De Gruyter

     Dr Emmanuel J Favaloro

184. 
     A multi-laboratory assessment of congenital thrombophilia assays performed on the ACL TOP 50 family for harmonisation of thrombophilia testing in a large laboratory network

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), June 2021, De Gruyter

     Dr Emmanuel J Favaloro

185. 
     Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19): Part II

     Article • Seminars in Thrombosis and Hemostasis, June 2021, Thieme Publishing Group

     Dr Emmanuel J Favaloro

186. 
     Variability in D-dimer reporting revisited

     Article • Pathology, June 2021, Elsevier

     Dr Emmanuel J Favaloro

187. 
     Laboratory testing for ADAMTS13: Utility for TTP diagnosis/exclusion and beyond

     Article • American Journal of Hematology, May 2021, Wiley

     Dr Emmanuel J Favaloro

188. 
     The complicated relationships of heparin‐induced thrombocytopenia and platelet factor 4 antibodies with COVID‐19

     Article • International Journal of Laboratory Hematology, May 2021, Wiley

     Dr Emmanuel J Favaloro

189. 
     Verification of the ACL Top 50 Family (350, 550, and 750) for Harmonization of Routine Coagulation Assays in a Large Network of 60 Laboratories

     Article • American Journal of Clinical Pathology, April 2021, Oxford University Press (OUP)

     Dr Emmanuel J Favaloro

190. 
     Mean Platelet Volume Predicts Severe COVID-19 Illness

     Article • Seminars in Thrombosis and Hemostasis, April 2021, Thieme Publishing Group

     Dr Emmanuel J Favaloro

191. 
     Increased VWF and Decreased ADAMTS-13 in COVID-19: Creating a Milieu for (Micro)Thrombosis

     Article • Seminars in Thrombosis and Hemostasis, April 2021, Thieme Publishing Group

     Dr Emmanuel J Favaloro

192. 
     2021 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

     Article • Seminars in Thrombosis and Hemostasis, April 2021, Thieme Publishing Group

     Dr Emmanuel J Favaloro

193. 
     Effect of sample heat inactivation on test levels of HIT-IgG(PF4-H) detected by the ACL AcuStar

     Article • Thrombosis Research, April 2021, Elsevier

     Dr Emmanuel J Favaloro

194. 
     2020 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards

     Article • Seminars in Thrombosis and Hemostasis, April 2021, Thieme Publishing Group

     Dr Emmanuel J Favaloro

195. 
     Heparin-induced thrombocytopenia: pathophysiology, diagnosis and treatment

     Article • Expert Review of Hematology, March 2021, Taylor & Francis

     Dr Emmanuel J Favaloro

196. 
     2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants

     Article • Thrombosis and Haemostasis, March 2021, Thieme Publishing Group

     Dr Emmanuel J Favaloro

197. 
     Machine learning and coagulation testing: the next big thing in hemostasis investigations?

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), March 2021, De Gruyter

     Dr Emmanuel J Favaloro

198. 
     A multicenter laboratory assessment of a new automated chemiluminescent assay for ADAMTS13 activity

     Article • Journal of Thrombosis and Haemostasis, February 2021, Elsevier

     Dr Emmanuel J Favaloro

199. 
     A multicentre assessment of contemporary laboratory assays for heparin induced thrombocytopenia

     Article • Pathology, February 2021, Elsevier

     Dr Emmanuel J Favaloro

200. 
     Editorial Compilation IX

     Article • Seminars in Thrombosis and Hemostasis, February 2021, Thieme Publishing Group

     Dr Emmanuel J Favaloro

201. 
     Welcome to Seminars in Thrombosis & Hemostasis 2021—New (2019) Impact Factor and Most Highly Cited Papers

     Article • Seminars in Thrombosis and Hemostasis, February 2021, Thieme Publishing Group

     Dr Emmanuel J Favaloro

202. 
     Circulating Levels of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 Are Independent Predictors of Coronavirus Disease 2019 Severity: A Prospective, Observational Study

     Article • Seminars in Thrombosis and Hemostasis, January 2021, Thieme Publishing Group

     Dr Emmanuel J Favaloro

203. 
     2B or not 2B? A diagnosis of von Willebrand disease a lifetime of 86 years in the making

     Article • Blood Coagulation & Fibrinolysis, January 2021, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

204. 
     Coronavirus Disease 2019–Associated Coagulopathy

     Article • Mayo Clinic Proceedings, January 2021, Elsevier

     Dr Emmanuel J Favaloro

205. 
     ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID‐19: Evidence of SARS‐CoV‐2 induced secondary thrombotic microangiopathy

     Article • International Journal of Laboratory Hematology, December 2020, Wiley

     Dr Emmanuel J Favaloro

206. 
     Sample stability for routine coagulation testing

     Article • Thrombosis Research, December 2020, Elsevier

     Dr Emmanuel J Favaloro

207. 
     D-dimer measurement in COVID-19: Silver bullet or clinical distraction?

     Article • Thrombosis Research, December 2020, Elsevier

     Dr Emmanuel J Favaloro

208. 
     How we diagnose 2M von Willebrand disease (VWD): Use of a strategic algorithmic approach to distinguish 2M VWD from other VWD types

     Article • Haemophilia, November 2020, Wiley

     Dr Emmanuel J Favaloro

209. 
     Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis

     Article • Journal of Thrombosis and Haemostasis, November 2020, Elsevier

     Dr Emmanuel J Favaloro

210. 
     Oral anticoagulation therapy: an update on usage, costs and associated risks

     Article • Pathology, October 2020, Elsevier

     Dr Emmanuel J Favaloro

211. 
     Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19)—Part I

     Article • Seminars in Thrombosis and Hemostasis, October 2020, Thieme Publishing Group

     Dr Emmanuel J Favaloro

212. 
     Plasma vs serum as test sample for the chemiluminescent AcuStar HemosIL HIT‐IgG(PF4‐H) assay

     Article • International Journal of Laboratory Hematology, September 2020, Wiley

     Dr Emmanuel J Favaloro

213. 
     Standardization of Prothrombin Time/International Normalized Ratio (PT/INR)

     Article • International Journal of Laboratory Hematology, September 2020, Wiley

     Dr Emmanuel J Favaloro

214. 
     Periodontal Disease and Venous Thromboembolism

     Article • Seminars in Thrombosis and Hemostasis, September 2020, Thieme Publishing Group

     Dr Emmanuel J Favaloro

215. 
     Circulating Plasminogen Concentration at Admission in Patients with Coronavirus Disease 2019 (COVID-19)

     Article • Seminars in Thrombosis and Hemostasis, September 2020, Thieme Publishing Group

     Dr Emmanuel J Favaloro

216. 
     Hematology Laboratory Abnormalities in Patients with Coronavirus Disease 2019 (COVID-19)

     Article • Seminars in Thrombosis and Hemostasis, September 2020, Thieme Publishing Group

     Dr Emmanuel J Favaloro

217. 
     “Systematic review of viscoelastic testing (TEG/ROTEM) in obstetrics and recommendation from the women's SSC of the ISTH”: Response to comment from Kitchen et al

     Article • Journal of Thrombosis and Haemostasis, September 2020, Elsevier

     Dr Emmanuel J Favaloro

218. 
     Anticoagulant and antithrombotic therapy: globally applied according to local geographical selection criteria

     Article • Annals of Blood, September 2020, AME Publishing Company

     Dr Emmanuel J Favaloro

219. 
     Novel approaches to ensuring quality in laboratory diagnostics and external quality assessment

     Article • Annals of Blood, September 2020, AME Publishing Company

     Dr Emmanuel J Favaloro

220. 
     Statins and other drugs: Facing COVID-19 as a vascular disease

     Article • Pharmacological Research, September 2020, Elsevier

     Dr Emmanuel J Favaloro

221. 
     The need for accurate D‐dimer reporting in COVID‐19: Communication from the ISTH SSC on fibrinolysis

     Article • Journal of Thrombosis and Haemostasis, September 2020, Elsevier

     Dr Emmanuel J Favaloro

222. 
     Classification of von Willebrand disease in the context of modern contemporary von Willebrand factor testing methodologies

     Article • Research and Practice in Thrombosis and Haemostasis, August 2020, Elsevier

     Dr Emmanuel J Favaloro

223. 
     Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis

     Article • Clinica Chimica Acta, August 2020, Elsevier

     Dr Emmanuel J Favaloro

224. 
     Periodontitis, coronary heart disease and myocardial infarction: treat one, benefit all

     Article • Blood Coagulation & Fibrinolysis, July 2020, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

225. 
     Navigating the Myriad of von Willebrand Factor Assays

     Article • Hämostaseologie, June 2020, Thieme Publishing Group

     Dr Emmanuel J Favaloro

226. 
     COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up

     Article • Journal of the American College of Cardiology, June 2020, Elsevier

     Dr Emmanuel J Favaloro

227. 
     2020 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

     Article • Seminars in Thrombosis and Hemostasis, June 2020, Thieme Publishing Group

     Dr Emmanuel J Favaloro

228. 
     Antisense lipoprotein[a] therapy: State-of-the-art and future perspectives

     Article • European Journal of Internal Medicine, June 2020, Elsevier

     Dr Emmanuel J Favaloro

229. 
     Editorial Compilation VIII

     Article • Seminars in Thrombosis and Hemostasis, June 2020, Thieme Publishing Group

     Dr Emmanuel J Favaloro

230. 
     Gene therapy for hemophilias: the end of phenotypic testing or the start of a new era?

     Article • Blood Coagulation & Fibrinolysis, June 2020, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

231. 
     The effect of DOACs on laboratory tests and their removal by activated carbon to limit interference in functional assays

     Article • International Journal of Laboratory Hematology, June 2020, Wiley

     Dr Emmanuel J Favaloro

232. 
     Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research

     Article • Thrombosis and Haemostasis, May 2020, Thieme Publishing Group

     Dr Emmanuel J Favaloro

233. 
     Reporting of D-dimer data in COVID-19: some confusion and potential for misinformation

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), May 2020, De Gruyter

     Dr Emmanuel J Favaloro

234. 
     COVID-19: progression of disease and intravascular coagulation – present status and future perspectives

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), May 2020, De Gruyter

     Dr Emmanuel J Favaloro

235. 
     Mean platelet volume in arterial and venous thrombotic disorders

     Article • Journal of Laboratory Medicine, April 2020, De Gruyter

     Giuseppe Lippi, Dr Emmanuel J Favaloro

236. 
     D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis

     Article • Thrombosis and Haemostasis, April 2020, Thieme Publishing Group

     Dr Emmanuel J Favaloro

237. 
     Recommendations for Minimal Laboratory Testing Panels in Patients with COVID-19: Potential for Prognostic Monitoring

     Article • Seminars in Thrombosis and Hemostasis, April 2020, Thieme Publishing Group

     Dr Emmanuel J Favaloro

238. 
     Utility of the platelet function analyser (PFA-100/200) for exclusion or detection of von Willebrand disease: A study 22 years in the making

     Article • Thrombosis Research, April 2020, Elsevier

     Dr Emmanuel J Favaloro

239. 
     Mixing studies for lupus anticoagulant: mostly yes, sometimes no

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), March 2020, De Gruyter

     Dr Emmanuel J Favaloro

240. 
     Comparative assessment of von Willebrand factor multimers vs activity for von Willebrand disease using modern contemporary methodologies

     Article • Haemophilia, March 2020, Wiley

     Dr Emmanuel J Favaloro

241. 
     Laboratory testing for activated protein C resistance: rivaroxaban induced interference and a comparative evaluation of andexanet alfa and DOAC Stop to neutralise interference

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), March 2020, De Gruyter

     Dr Emmanuel J Favaloro

242. 
     Impact of water temperature on reconstitution of quality controls for routine hemostasis testing

     Article • Diagnosis, February 2020, De Gruyter

     Dr Emmanuel J Favaloro

243. 
     Welcome to Seminars in Thrombosis and Hemostasis 2020—New (2018) Impact Factor and Most Highly Cited Papers

     Article • Seminars in Thrombosis and Hemostasis, February 2020, Thieme Publishing Group

     Dr Emmanuel J Favaloro

244. 
     Dental extractions on direct oral anticoagulants vs. warfarin: The DENTST study

     Article • Research and Practice in Thrombosis and Haemostasis, February 2020, Elsevier

     Dr Emmanuel J Favaloro

245. 
     Unfractionated heparin monitoring with activated partial thromboplastin time

     Article • Pathology, February 2020, Elsevier

     Dr Emmanuel J Favaloro

246. 
     Reducing the effect of DOAC interference in laboratory testing for factor VIII and factor IX: A comparative study using DOAC Stop and andexanet alfa to neutralize rivaroxaban effects

     Article • Haemophilia, January 2020, Wiley

     Dr Emmanuel J Favaloro

247. 
     Understanding the extent of the diagnostic potential of coagulation factors

     Article • Expert Review of Molecular Diagnostics, January 2020, Taylor & Francis

     Dr Emmanuel J Favaloro

248. 
     An Update on Biological and Clinical Associations between E-Cigarettes and Myocardial Infarction

     Article • Seminars in Thrombosis and Hemostasis, December 2019, Thieme Publishing Group

     Dr Emmanuel J Favaloro

249. 
     Direct Oral Anticoagulants for Disseminated Intravascular Coagulation: An Alliterative Wordplay or Potentially Valuable Therapeutic Interventions?

     Article • Seminars in Thrombosis and Hemostasis, December 2019, Thieme Publishing Group

     Dr Emmanuel J Favaloro

250. 
     Coagulation studies: achieving the right mix in a large laboratory network

     Article • Pathology, December 2019, Elsevier

     Dr Emmanuel J Favaloro

251. 
     The Pointy End of Point-of-Care Testing for Direct Oral Anticoagulants

     Article • Thrombosis and Haemostasis, November 2019, Thieme Publishing Group

     Dr Emmanuel J Favaloro

252. 
     Coagulation mixing studies: Utility, algorithmic strategies and limitations for lupus anticoagulant testing or follow up of abnormal coagulation tests

     Article • American Journal of Hematology, November 2019, Wiley

     Dr Emmanuel J Favaloro

253. 
     International Council for Standardization in Haematology Recommendations for Hemostasis Critical Values, Tests, and Reporting

     Article • Seminars in Thrombosis and Hemostasis, October 2019, Thieme Publishing Group

     Dr Emmanuel J Favaloro

254. 
     Measurement of High-Sensitivity Cardiac Troponin in Pulmonary Embolism: Useful Test or a Clinical Distraction

     Article • Seminars in Thrombosis and Hemostasis, October 2019, Thieme Publishing Group

     Dr Emmanuel J Favaloro

255. 
     Drug-Induced Thrombocytopenia: Mechanisms and Laboratory Diagnostics

     Article • Seminars in Thrombosis and Hemostasis, September 2019, Thieme Publishing Group

     Dr Emmanuel J Favaloro

256. 
     Platelet Transfusion Thresholds: How Low Can We Go in Respect to Platelet Counting?

     Article • Seminars in Thrombosis and Hemostasis, September 2019, Thieme Publishing Group

     Dr Emmanuel J Favaloro

257. 
     Semi‐automated von Willebrand factor multimer assay for von Willebrand disease: Further validation, benefits and limitations

     Article • International Journal of Laboratory Hematology, September 2019, Wiley

     Dr Emmanuel J Favaloro

258. 
     A diagnosis of von Willebrand disease despite normal test results for factor VIII and von Willebrand factor antigen and activity

     Article • American Journal of Hematology, August 2019, Wiley

     Dr Emmanuel J Favaloro

259. 
     The Russell viper venom time (RVVT) test for investigation of lupus anticoagulant (LA)

     Article • American Journal of Hematology, August 2019, Wiley

     Dr Emmanuel J Favaloro

260. 
     The Model List of Essential In Vitro Diagnostics: nuisance or opportunity?

     Article • Diagnosis, August 2019, De Gruyter

     Giuseppe Lippi, Dr Emmanuel J Favaloro

261. 
     Understanding the “philosophy” of laboratory hemostasis

     Article • Diagnosis, August 2019, De Gruyter

     Giuseppe Lippi, Dr Emmanuel J Favaloro

262. 
     Genetic Testing for Thrombophilia-Related Genes: Observations of Testing Patterns for Factor V Leiden (G1691A) and Prothrombin Gene “Mutation” (G20210A)

     Article • Seminars in Thrombosis and Hemostasis, August 2019, Thieme Publishing Group

     Dr Emmanuel J Favaloro

263. 
     Neutralising rivaroxaban induced interference in laboratory testing for lupus anticoagulant (LA): A comparative study using DOAC Stop and andexanet alfa

     Article • Thrombosis Research, August 2019, Elsevier

     Dr Emmanuel J Favaloro

264. 
     Development and implementation of an expert rule set for automated reflex testing and validation of routine coagulation tests in a large pathology network

     Article • International Journal of Laboratory Hematology, July 2019, Wiley

     Dr Emmanuel J Favaloro

265. 
     Editorial Compilation VII

     Article • Seminars in Thrombosis and Hemostasis, July 2019, Thieme Publishing Group

     Dr Emmanuel J Favaloro

266. 
     Current and Emerging Direct Oral Anticoagulants: State-of-the-Art

     Article • Seminars in Thrombosis and Hemostasis, June 2019, Thieme Publishing Group

     Dr Emmanuel J Favaloro

267. 
     Diagnosis and management of heparin‐induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New ZealandHITWriting Group

     Article • The Medical Journal of Australia, June 2019, Australasian Medical Publishing Co. Pty Ltd. (AMPCo)

     Marie-Christine Morel-Kopp, Dr Emmanuel J Favaloro

268. 
     Statins for Preventing Venous Thrombosis: For or Against?

     Article • Seminars in Thrombosis and Hemostasis, May 2019, Thieme Publishing Group

     Dr Emmanuel J Favaloro

269. 
     Vascular Disease and Dementia: Lipoprotein(a) as a Neglected Link

     Article • Seminars in Thrombosis and Hemostasis, May 2019, Thieme Publishing Group

     Dr Emmanuel J Favaloro

270. 
     Impact of low volume citrate tubes on results of first‐line hemostasis testing

     Article • International Journal of Laboratory Hematology, April 2019, Wiley

     Dr Emmanuel J Favaloro

271. 
     Influence of hypertriglyceridemia, hyperbilirubinemia and hemolysis on thrombin generation in human plasma

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), April 2019, De Gruyter

     Giuseppe Lippi, Dr Emmanuel J Favaloro

272. 
     2019 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

     Article • Seminars in Thrombosis and Hemostasis, April 2019, Thieme Publishing Group

     Dr Emmanuel J Favaloro

273. 
     Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives

     Article • Pathology, April 2019, Elsevier

     Dr Emmanuel J Favaloro

274. 
     Thrombin generation in different commercial sodium citrate blood tubes

     Article • Journal of Medical Biochemistry, March 2019, Centre for Evaluation in Education and Science (CEON/CEES)

     Dr Emmanuel J Favaloro

275. 
     Recent Advances in Mainstream Hemostasis Diagnostics and Coagulation Testing

     Article • Seminars in Thrombosis and Hemostasis, March 2019, Thieme Publishing Group

     Dr Emmanuel J Favaloro

276. 
     2018 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards

     Article • Seminars in Thrombosis and Hemostasis, March 2019, Thieme Publishing Group

     Dr Emmanuel J Favaloro

277. 
     To Maintain or Cease Non–Vitamin K Antagonist Oral Anticoagulants Prior to Minimal Bleeding Risk Procedures: A Review of Evidence and Recommendations

     Article • Seminars in Thrombosis and Hemostasis, February 2019, Thieme Publishing Group

     Dr Emmanuel J Favaloro

278. 
     Analytical Assessment of the New Roche Cobas t 711 Fully Automated Coagulation Analyzer

     Article • Seminars in Thrombosis and Hemostasis, January 2019, Thieme Publishing Group

     Dr Davide Giavarina, Dr Emmanuel J Favaloro

279. 
     Editorial Compilation VI

     Article • Seminars in Thrombosis and Hemostasis, January 2019, Thieme Publishing Group

     Dr Emmanuel J Favaloro

280. 
     Welcome to Seminars in Thrombosis and Hemostasis 2019–New (2017) Impact Factor and Most Highly Cited Papers

     Article • Seminars in Thrombosis and Hemostasis, January 2019, Thieme Publishing Group

     Dr Emmanuel J Favaloro

281. 
     Commentary: Controversies in Thrombosis and Hemostasis Part 2–Does Sticky Platelet Syndrome Exist?

     Article • Seminars in Thrombosis and Hemostasis, January 2019, Thieme Publishing Group

     Dr Emmanuel J Favaloro

282. 
     How to Optimize Activated Partial Thromboplastin Time (APTT) Testing: Solutions to Establishing and Verifying Normal Reference Intervals and Assessing APTT Reagents for Sensitivity to Heparin, Lupus Anticoagulant, and Clotting Factors

     Article • Seminars in Thrombosis and Hemostasis, January 2019, Thieme Publishing Group

     Dr Emmanuel J Favaloro

283. 
     Emicizumab (ACE910): Clinical background and laboratory assessment of hemophilia A

     Article • January 2019, Elsevier

     Dr Emmanuel J Favaloro

284. 
     Lessons learnt from local real‐life experience with idarucizumab for the reversal of dabigatran

     Article • Internal Medicine Journal, January 2019, Wiley

     Dr Emmanuel J Favaloro

285. 
     Analytical performance of the new D‐dimer and antithrombin assay on Roche cobas t 711 analyzer

     Article • International Journal of Laboratory Hematology, December 2018, Wiley

     Dr Emmanuel J Favaloro

286. 
     Dark chocolate modulates platelet function with a mechanism mediated by flavan-3-ol metabolites

     Article • Medicine, December 2018, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

287. 
     Danger of false negative (exclusion) or false positive (diagnosis) for ‘congenital thrombophilia’ in the age of anticoagulants

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), November 2018, De Gruyter

     Dr Emmanuel J Favaloro

288. 
     Harms and Benefits of Using Aspirin for Primary Prevention of Cardiovascular Disease: A Narrative Overview

     Article • Seminars in Thrombosis and Hemostasis, October 2018, Thieme Publishing Group

     Dr Emmanuel J Favaloro

289. 
     Anticoagulation at the extremes of body weight: choices and dosing

     Article • Expert Review of Hematology, September 2018, Taylor & Francis

     Dr Jennifer Curnow, Dr Emmanuel J Favaloro

290. 
     Rare forms of von Willebrand disease

     Article • Annals of Translational Medicine, September 2018, AME Publishing Company

     Dr Emmanuel J Favaloro

291. 
     e-thrombosis: epidemiology, physiopathology and rationale for preventing computer-related thrombosis

     Article • Annals of Translational Medicine, September 2018, AME Publishing Company

     Dr Emmanuel J Favaloro

292. 
     How to Generate a More Accurate Laboratory-Based International Normalized Ratio: Solutions to Obtaining or Verifying the Mean Normal Prothrombin Time and International Sensitivity Index

     Article • Seminars in Thrombosis and Hemostasis, August 2018, Thieme Publishing Group

     Dr Emmanuel J Favaloro

293. 
     Prothrombotic State Induced by Middle-Distance Endurance Exercise in Middle-Aged Athletes

     Article • Seminars in Thrombosis and Hemostasis, August 2018, Thieme Publishing Group

     Dr Emmanuel J Favaloro

294. 
     Postanalytical considerations that may improve the diagnosis or exclusion of haemophilia and von Willebrand disease

     Article • Haemophilia, July 2018, Wiley

     Dr Emmanuel J Favaloro

295. 
     Laboratory hemostasis: from biology to the bench

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), June 2018, De Gruyter

     Giuseppe Lippi, Dr Emmanuel J Favaloro

296. 
     45 years of Seminars in Thrombosis and Hemostasis

     Article • Seminars in Thrombosis and Hemostasis, June 2018, Thieme Publishing Group

     Dr Emmanuel J Favaloro

297. 
     Myocardial Infarction, Unstable Angina, and White Thrombi: Time to Move Forward?

     Article • Seminars in Thrombosis and Hemostasis, June 2018, Thieme Publishing Group

     Dr Emmanuel J Favaloro

298. 
     Sudden Cardiac and Noncardiac Death in Sports: Epidemiology, Causes, Pathogenesis, and Prevention

     Article • Seminars in Thrombosis and Hemostasis, June 2018, Thieme Publishing Group

     Dr Emmanuel J Favaloro

299. 
     A 2018 Update on the Editorial and Publication Policy of Seminars in Thrombosis and Hemostasis

     Article • Seminars in Thrombosis and Hemostasis, June 2018, Thieme Publishing Group

     Dr Emmanuel J Favaloro

300. 
     Differential sensitivity of von Willebrand factor activity assays to reduced VWF molecular weight forms: A large international cross-laboratory study

     Article • Thrombosis Research, June 2018, Elsevier

     Dr Emmanuel J Favaloro

301. 
     HIT or miss? A comprehensive contemporary investigation of laboratory tests for heparin induced thrombocytopenia

     Article • Pathology, June 2018, Elsevier

     Dr Emmanuel J Favaloro

302. 
     Mathematical rounding as a post-analytical issue in pathology reporting: generation of bias in INR resulting

     Article • Pathology, June 2018, Elsevier

     Dr Emmanuel J Favaloro

303. 
     An update on quality control for the PFA-100/PFA-200

     Article • Platelets, May 2018, Taylor & Francis

     Dr Emmanuel J Favaloro

304. 
     Car Travel-Related Thrombosis: Fact or Fiction?

     Article • Seminars in Thrombosis and Hemostasis, May 2018, Thieme Publishing Group

     Dr Emmanuel J Favaloro

305. 
     Not as sweet as honey: A rare case of an apparent factor V “inhibitor” in association with bee sting anaphylaxis

     Article • American Journal of Hematology, May 2018, Wiley

     Dr Emmanuel J Favaloro

306. 
     Recent initiatives in harmonization of hemostasis practice

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), May 2018, De Gruyter

     Dr Emmanuel J Favaloro

307. 
     On the complexity of hemostasis and the need for harmonization of test practice

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), May 2018, De Gruyter

     Dr Emmanuel J Favaloro

308. 
     Towards harmonization of external quality assessment/proficiency testing in hemostasis

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), April 2018, De Gruyter

     Dr Emmanuel J Favaloro

309. 
     Management of pregnancy complications in type 2N von Willebrand disease associated to a novel mutation

     Article • Haemophilia, April 2018, Wiley

     Dr Emmanuel J Favaloro

310. 
     2018 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

     Article • Seminars in Thrombosis and Hemostasis, April 2018, Thieme Publishing Group

     Dr Emmanuel J Favaloro

311. 
     Editorial Compilation V

     Article • Seminars in Thrombosis and Hemostasis, April 2018, Thieme Publishing Group

     Dr Emmanuel J Favaloro

312. 
     2017 Eberhard F. Mammen Award Announcements: Part II–Young Investigator Awards

     Article • Seminars in Thrombosis and Hemostasis, February 2018, Thieme Publishing Group

     Dr Emmanuel J Favaloro

313. 
     International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants

     Article • Thrombosis and Haemostasis, February 2018, Thieme Publishing Group

     Dr Emmanuel J Favaloro

314. 
     Welcome to Seminars in Thrombosis & Hemostasis 2018. New (2016) Impact Factor and Most Highly Cited Papers

     Article • Seminars in Thrombosis and Hemostasis, February 2018, Thieme Publishing Group

     Dr Emmanuel J Favaloro

315. 
     Assessment of Plasma Sample Quality on Siemens Atellica COAG 360 System

     Article • Seminars in Thrombosis and Hemostasis, January 2018, Thieme Publishing Group

     Dr Emmanuel J Favaloro

316. 
     von Willebrand Disease

     Article • January 2018, Springer Science + Business Media

     Shadi Tabibin , Dr Emmanuel J Favaloro

317. 
     von Willebrand Disease

     Article • January 2018, Elsevier

     Dr Emmanuel J Favaloro

318. 
     Lack of grading agreement among international hemostasis external quality assessment programs

     Article • Blood Coagulation & Fibrinolysis, January 2018, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

319. 
     Preanalytical issues that may cause misdiagnosis in haemophilia and von Willebrand disease

     Article • Haemophilia, December 2017, Wiley

     Dr Emmanuel J Favaloro

320. 
     Commentary: Controversies in Thrombosis and Hemostasis Part 1—Hematidrosis: “Blood, Sweat and Fears” or A “Pigment of Fertile Imaginations?”

     Article • Seminars in Thrombosis and Hemostasis, December 2017, Thieme Publishing Group

     Dr Emmanuel J Favaloro

321. 
     Laboratory tests for identification or exclusion of heparin induced thrombocytopenia: HIT or miss?

     Article • American Journal of Hematology, December 2017, Wiley

     Dr Emmanuel J Favaloro

322. 
     Time dependent reduction in platelet aggregation using the multiplate analyser and hirudin blood due to platelet clumping

     Article • Platelets, December 2017, Taylor & Francis

     Dr Emmanuel J Favaloro

323. 
     Trenonacog alfa for prophylaxis, on-demand and perioperative management of hemophilia B

     Article • Expert Opinion on Biological Therapy, November 2017, Taylor & Francis

     Dr Emmanuel J Favaloro

324. 
     The increasing maturity of the von Willebrand factor collagen binding in von Willebrand disease diagnosis

     Article • Haemophilia, November 2017, Wiley

     Dr Emmanuel J Favaloro

325. 
     Replacing warfarin therapy with the newer direct oral anticoagulants, or simply a growth in anticoagulation therapy? Implications for pathology testing

     Article • Pathology, October 2017, Elsevier

     Dr Emmanuel J Favaloro

326. 
     Venous and Arterial Thromboses: Two Sides of the Same Coin?

     Article • Seminars in Thrombosis and Hemostasis, September 2017, Thieme Publishing Group

     Dr Emmanuel J Favaloro

327. 
     Laboratory Monitoring or Measurement of Direct Oral Anticoagulants (DOACs): Advantages, Limitations and Future Challenges

     Article • Current Drug Metabolism, September 2017, Bentham Science Publishers

     Dr Emmanuel J Favaloro

328. 
     Gender related issues in thrombosis and hemostasis

     Article • Expert Review of Hematology, August 2017, Taylor & Francis

     Dr Emmanuel J Favaloro

329. 
     Editorial Compilation IV

     Article • Seminars in Thrombosis and Hemostasis, August 2017, Thieme Publishing Group

     Dr Emmanuel J Favaloro

330. 
     Direct oral anticoagulants: analysis of worldwide use and popularity using Google Trends

     Article • Annals of Translational Medicine, August 2017, AME Publishing Company

     Dr Emmanuel J Favaloro

331. 
     Potential misdiagnosis of von Willebrand disease and haemophilia caused by ineffective mixing of thawed plasma

     Article • Haemophilia, July 2017, Wiley

     Dr Gabriel Lima-Oliveira, Dr Emmanuel J Favaloro

332. 
     Managing the patient identification crisis in healthcare and laboratory medicine

     Article • Clinical Biochemistry, July 2017, Elsevier

     Dr Emmanuel J Favaloro

333. 
     Therapeutic monitoring of unfractionated heparin – trials and tribulations

     Article • Expert Review of Hematology, June 2017, Taylor & Francis

     Dr Emmanuel J Favaloro

334. 
     Novel (Oral) Anticoagulant Challenges in Surgery

     Article • Seminars in Thrombosis and Hemostasis, June 2017, Thieme Publishing Group

     Dr Emmanuel J Favaloro

335. 
     Serum Concentration of Growth Differentiation Factor-15 Is Independently Associated with Global Platelet Function and Higher Fibrinogen Values in Adult Healthy Subjects

     Article • Seminars in Thrombosis and Hemostasis, June 2017, Thieme Publishing Group

     Dr Emmanuel J Favaloro

336. 
     Clinical and laboratory diagnosis of heparin induced thrombocytopenia: an update

     Article • Pathology, June 2017, Elsevier

     Dr Emmanuel J Favaloro

337. 
     2017 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

     Article • Seminars in Thrombosis and Hemostasis, May 2017, Thieme Publishing Group

     Dr Emmanuel J Favaloro

338. 
     Evaluation of a new commercial von Willebrand factor multimer assay

     Article • Haemophilia, May 2017, Wiley

     Dr Emmanuel J Favaloro

339. 
     2B or not 2B? A prothrombotic tendency masquerading as a bleeding disorder

     Article • American Journal of Hematology, May 2017, Wiley

     Dr Emmanuel J Favaloro

340. 
     Translational aspects of developmental hemostasis: infants and children are not miniature adults and even adults may be different

     Article • Annals of Translational Medicine, May 2017, AME Publishing Company

     Dr Emmanuel J Favaloro

341. 
     Impact of experimental hypercalcemia on routine haemostasis testing

     Article • PLOS One, March 2017, PLOS

     Dr Emmanuel J Favaloro

342. 
     2016 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards

     Article • Seminars in Thrombosis and Hemostasis, March 2017, Thieme Publishing Group

     Dr Emmanuel J Favaloro

343. 
     The Intriguing Link between the Intestinal Microbiota and Cardiovascular Disease

     Article • Seminars in Thrombosis and Hemostasis, March 2017, Thieme Publishing Group

     Dr Emmanuel J Favaloro

344. 
     Platelet function testing in pediatric patients

     Article • Expert Review of Hematology, March 2017, Taylor & Francis

     Dr Emmanuel J Favaloro

345. 
     Emerging treatments for hemophilia: patients and their treaters spoilt for choice, but laboratories face a difficult path?

     Article • Annals of Translational Medicine, March 2017, AME Publishing Company

     Dr Emmanuel J Favaloro

346. 
     Welcome to Seminars in Thrombosis & Hemostasis 2017 — New (2015) Impact Factor and Most Highly Cited Papers

     Article • Seminars in Thrombosis and Hemostasis, February 2017, Thieme Publishing Group

     Dr Emmanuel J Favaloro

347. 
     Editorial Compilation III

     Article • Seminars in Thrombosis and Hemostasis, February 2017, Thieme Publishing Group

     Dr Emmanuel J Favaloro

348. 
     Critical laboratory values in hemostasis: toward consensus

     Article • Annals of Medicine, February 2017, Taylor & Francis

     Dr Emmanuel J Favaloro

349. 
     Clinical utility of closure times using the platelet function analyzer‐100/200

     Article • American Journal of Hematology, February 2017, Wiley

     Dr Emmanuel J Favaloro

350. 
     Explaining and reducing the variation in inter-laboratory reported values for International Normalised Ratio

     Article • Thrombosis Research, February 2017, Elsevier

     Dr Emmanuel J Favaloro

351. 
     Exploring the iceberg of inappropriateness in hemostasis testing

     Article • Diagnosis, January 2017, De Gruyter

     Giuseppe Lippi, Dr Emmanuel J Favaloro

352. 
     Diagnosis or Exclusion of von Willebrand Disease Using Laboratory Testing

     Article • January 2017, Springer Science + Business Media

     Dr Emmanuel J Favaloro

353. 
     Laboratory Testing for von Willebrand Factor: Factor VIII Binding (for 2N VWD)

     Article • January 2017, Springer Science + Business Media

     Dr Emmanuel J Favaloro

354. 
     Laboratory Testing for von Willebrand Factor Ristocetin Cofactor (VWF:RCo)

     Article • January 2017, Springer Science + Business Media

     Dr Emmanuel J Favaloro

355. 
     Laboratory Testing for Activated Protein C Resistance (APCR)

     Article • January 2017, Springer Science + Business Media

     Dr Emmanuel J Favaloro

356. 
     Laboratory Testing for Von Willebrand Factor Multimers

     Article • January 2017, Springer Science + Business Media

     Dr Emmanuel J Favaloro

357. 
     Laboratory Testing for von Willebrand Factor Antigen (VWF:Ag)

     Article • January 2017, Springer Science + Business Media

     Dr Emmanuel J Favaloro

358. 
     Laboratory Testing for von Willebrand Factor Collagen Binding (VWF:CB)

     Article • January 2017, Springer Science + Business Media

     Dr Emmanuel J Favaloro

359. 
     Laboratory Testing for von Willebrand Factor Activity by Glycoprotein Ib Binding Assays (VWF:GPIb)

     Article • January 2017, Springer Science + Business Media

     Dr Emmanuel J Favaloro

360. 
     Laboratory Testing Protocols for Heparin-Induced Thrombocytopenia (HIT) Testing

     Article • January 2017, Springer Science + Business Media

     Dr Emmanuel J Favaloro

361. 
     Optimizing the Verification of Mean Normal Prothrombin Time (MNPT) and International Sensitivity Index (ISI) for Accurate Conversion of Prothrombin Time (PT) to International Normalized Ratio (INR)

     Article • January 2017, Springer Science + Business Media

     Dr Emmanuel J Favaloro

362. 
     Overview of Hemostasis and Thrombosis and Contribution of Laboratory Testing to Diagnosis and Management of Hemostasis and Thrombosis Disorders

     Article • January 2017, Springer Science + Business Media

     Dr Emmanuel J Favaloro

363. 
     Platelet Function Analyzed by Light Transmission Aggregometry

     Article • January 2017, Springer Science + Business Media

     Dr Emmanuel J Favaloro

364. 
     Preanalytical Issues in Hemostasis and Thrombosis Testing

     Article • January 2017, Springer Science + Business Media

     Dr Emmanuel J Favaloro

365. 
     Ristocetin-Induced Platelet Aggregation (RIPA) and RIPA Mixing Studies

     Article • January 2017, Springer Science + Business Media

     Dr Emmanuel J Favaloro

366. 
     Laboratory monitoring of direct oral anticoagulants (DOACs)—The perfect storm?

     Article • Annals of Translational Medicine, January 2017, AME Publishing Company

     Dr Emmanuel J Favaloro

367. 
     D-Dimer Testing: Laboratory Aspects and Current Issues

     Article • January 2017, Springer Science + Business Media

     Dr Emmanuel J Favaloro

368. 
     Post-analytical Issues in Hemostasis and Thrombosis Testing

     Article • January 2017, Springer Science + Business Media

     Dr Emmanuel J Favaloro

369. 
     Critical pre-examination variables in the hemostasis laboratory and their quality indicators

     Article • Clinical Biochemistry, December 2016, Elsevier

     Dr Emmanuel J Favaloro

370. 
     Mixing of thawed coagulation samples prior to testing: Is any technique better than another?

     Article • Clinical Biochemistry, December 2016, Elsevier

     Dr Emmanuel J Favaloro

371. 
     Troubleshooting an isolate prolongation of activated partial thromboplastin time in a patient with acute myocardial infarction—a paradigmatic case report

     Article • Annals of Translational Medicine, November 2016, AME Publishing Company

     Dr Emmanuel J Favaloro

372. 
     Utility of the von Willebrand factor collagen binding assay in the diagnosis of von Willebrand disease

     Article • American Journal of Hematology, October 2016, Wiley

     Dr Emmanuel J Favaloro

373. 
     Giuseppe (Joseph) Favaloro (1922–2016)

     Article • Seminars in Thrombosis and Hemostasis, September 2016, Thieme Publishing Group

     Dr Emmanuel J Favaloro

374. 
     Editorial Compilation—II

     Article • Seminars in Thrombosis and Hemostasis, September 2016, Thieme Publishing Group

     Dr Emmanuel J Favaloro

375. 
     Monitoring Therapy during Treatment of von Willebrand Disease

     Article • Seminars in Thrombosis and Hemostasis, July 2016, Thieme Publishing Group

     Dr Emmanuel J Favaloro

376. 
     Laboratory tests used to help diagnose von Willebrand disease: an update

     Article • Pathology, June 2016, Elsevier

     Dr Emmanuel J Favaloro

377. 
     Andexanet: Effectively Reversing Anticoagulation

     Article • Trends in Pharmacological Sciences, June 2016, Elsevier

     Dr Emmanuel J Favaloro

378. 
     Characterizing the Mechanistic Pathways of the Instant Blood-Mediated Inflammatory Reaction in Xenogeneic Neonatal Islet Cell Transplantation

     Article • Transplantation Direct, June 2016, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

379. 
     Type 2M and Type 2A von Willebrand Disease: Similar but Different

     Article • Seminars in Thrombosis and Hemostasis, May 2016, Thieme Publishing Group

     Dr Emmanuel J Favaloro

380. 
     2016 Eberhard F. Mammen Award Announcements: Part I — Most Popular Articles

     Article • Seminars in Thrombosis and Hemostasis, May 2016, Thieme Publishing Group

     Dr Emmanuel J Favaloro

381. 
     Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand disease

     Article • Thrombosis Research, May 2016, Elsevier

     Dr Emmanuel J Favaloro

382. 
     Diagnostics of Inherited Bleeding Disorders of Secondary Hemostasis: An Easy Guide for Routine Clinical Laboratories

     Article • Seminars in Thrombosis and Hemostasis, April 2016, Thieme Publishing Group

     Giuseppe Lippi, Dr Emmanuel J Favaloro

383. 
     Human plasma-derived FVIII/VWD concentrate (Biostate): a review of experimental and clinical pharmacokinetic, efficacy and safety data

     Article • Drugs in Context, April 2016, BioExcel

     Dr Emmanuel J Favaloro

384. 
     Type 2M von Willebrand disease - more often misidentified than correctly identified

     Article • Haemophilia, March 2016, Wiley

     Dr Emmanuel J Favaloro

385. 
     Why Do Patients Bleed?

     Article • The Surgery Journal, February 2016, Thieme Publishing Group

     Dr Jennifer Curnow, Dr Emmanuel J Favaloro

386. 
     Editorial Compilation I

     Article • Seminars in Thrombosis and Hemostasis, February 2016, Thieme Publishing Group

     Dr Emmanuel J Favaloro

387. 
     Welcome to Seminars in Thrombosis & Hemostasis 2016: New (2014) Impact Factor and Most Highly Cited Articles

     Article • Seminars in Thrombosis and Hemostasis, February 2016, Thieme Publishing Group

     Dr Emmanuel J Favaloro

388. 
     Treatment of von Willebrand Disease

     Article • Seminars in Thrombosis and Hemostasis, February 2016, Thieme Publishing Group

     Dr Jennifer Curnow, Dr Emmanuel J Favaloro

389. 
     Harmonizing the International Normalized Ratio (INR)

     Article • American Journal of Clinical Pathology, January 2016, Oxford University Press (OUP)

     Dr Emmanuel J Favaloro

390. 
     Platelet type von Willebrand disease and registry report: communication from the SSC of the ISTH

     Article • Journal of Thrombosis and Haemostasis, January 2016, Wiley

     Dr Emmanuel J Favaloro

391. 
     Hereditary Thrombophilias: Pathophysiology, Timing of Testing and Familial Testing

     Article • January 2016, Springer Science + Business Media

     Dr Emmanuel J Favaloro

392. 
     Harmonisation of D-dimer — A call for action

     Article • Thrombosis Research, January 2016, Elsevier

     Dr Emmanuel J Favaloro

393. 
     The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples

     Article • Pathology, January 2016, Elsevier

     Dr Emmanuel J Favaloro

394. 
     Allergy and Venous Thromboembolism: A Casual or Causative Association

     Article • Seminars in Thrombosis and Hemostasis, December 2015, Thieme Publishing Group

     Giuseppe Lippi, Dr Emmanuel J Favaloro

395. 
     2015 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards

     Article • Seminars in Thrombosis and Hemostasis, November 2015, Thieme Publishing Group

     Dr Emmanuel J Favaloro

396. 
     2015 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

     Article • Seminars in Thrombosis and Hemostasis, October 2015, Thieme Publishing Group

     Dr Emmanuel J Favaloro

397. 
     Influence of posture on routine hemostasis testing

     Article • Blood Coagulation & Fibrinolysis, September 2015, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

398. 
     “Bleeding in the jungle”

     Article • American Journal of Hematology, August 2015, Wiley

     Dr Emmanuel J Favaloro

399. 
     Toward improved diagnosis of HIT

     Article • Blood, July 2015, American Society of Hematology

     Dr Emmanuel J Favaloro

400. 
     Recent advances in laboratory-aided diagnosis of von Willebrand disease

     Article • Expert Opinion on Orphan Drugs, July 2015, Informa Healthcare

     Dr Emmanuel J Favaloro

401. 
     Effect of contaminant 0.9% saline on tests of haemostasis

     Article • Anaesthesia, July 2015, Wiley

     Dr Emmanuel J Favaloro

402. 
     Commentary

     Article • Clinical Chemistry, July 2015, Oxford University Press (OUP)

     Dr Emmanuel J Favaloro

403. 
     Determining the stability of complete blood count parameters in stored blood samples using the SYSMEX XE-5000 automated haematology analyser

     Article • International Journal of Laboratory Hematology, June 2015, Wiley

     Dr Emmanuel J Favaloro

404. 
     Hot Topics VII

     Article • Seminars in Thrombosis and Hemostasis, June 2015, Thieme Publishing Group

     Dr Emmanuel J Favaloro

405. 
     Laboratory monitoring of warfarin in the era of direct oral anticoagulants

     Article • The Lancet Haematology, June 2015, Elsevier

     Dr Emmanuel J Favaloro

406. 
     The effect of dabigatran on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples

     Article • Pathology, June 2015, Elsevier

     Dr Emmanuel J Favaloro

407. 
     The Platelet Function Analyser (PFA)-100 and von Willebrand disease: a story well over 16 years in the making

     Article • Haemophilia, May 2015, Wiley

     Dr Emmanuel J Favaloro

408. 
     Pearls and pitfalls in factor inhibitor assays

     Article • International Journal of Laboratory Hematology, May 2015, Wiley

     Dr Emmanuel J Favaloro

409. 
     Detection of mild inherited disorders of blood coagulation: current options and personal recommendations

     Article • Expert Review of Hematology, April 2015, Taylor & Francis

     Dr Emmanuel J Favaloro

410. 
     Newer Hemostatic Agents

     Article • Seminars in Thrombosis and Hemostasis, April 2015, Thieme Publishing Group

     Dr Emmanuel J Favaloro

411. 
     Quality in Hemostasis and Thrombosis — Part IV

     Article • Seminars in Thrombosis and Hemostasis, April 2015, Thieme Publishing Group

     Dr Emmanuel J Favaloro

412. 
     Diagnostics in Venous Thromboembolism: From Origin to Future Prospects

     Article • Seminars in Thrombosis and Hemostasis, April 2015, Thieme Publishing Group

     Dr Emmanuel J Favaloro

413. 
     International Normalized Ratio Monitoring of Vitamin K Antagonist Therapy: Comparative Performance of Point-of-Care and Laboratory-Derived Testing

     Article • Seminars in Thrombosis and Hemostasis, April 2015, Thieme Publishing Group

     Dr Emmanuel J Favaloro

414. 
     International Survey on D-Dimer Test Reporting: A Call for Standardization

     Article • Seminars in Thrombosis and Hemostasis, April 2015, Thieme Publishing Group

     Dr Emmanuel J Favaloro

415. 
     Anticoagulant Therapy: Present and Future

     Article • Seminars in Thrombosis and Hemostasis, February 2015, Thieme Publishing Group

     Dr Emmanuel J Favaloro

416. 
     The Changing Face of Hemostasis Testing in Modern Laboratories: Consolidation, Automation, and Beyond

     Article • Seminars in Thrombosis and Hemostasis, February 2015, Thieme Publishing Group

     Dr Emmanuel J Favaloro

417. 
     Laboratory Testing in the Era of Direct or Non–Vitamin K Antagonist Oral Anticoagulants: A Practical Guide to Measuring Their Activity and Avoiding Diagnostic Errors

     Article • Seminars in Thrombosis and Hemostasis, February 2015, Thieme Publishing Group

     Dr Emmanuel J Favaloro

418. 
     Next Generation Antithrombotic Therapy: Focus on Antisense Therapy against Coagulation Factor XI

     Article • Seminars in Thrombosis and Hemostasis, February 2015, Thieme Publishing Group

     Job Harenberg, Dr Emmanuel J Favaloro

419. 
     Welcome to Seminars in Thrombosis & Hemostasis 2015: New (2013) Impact Factor and Most Highly Cited Articles

     Article • Seminars in Thrombosis and Hemostasis, February 2015, Thieme Publishing Group

     Dr Emmanuel J Favaloro

420. 
     Reflections on the next generation of hemostasis instrumentation. A glimpse into the future?

     Article • LaboratoriumsMedizin, January 2015, De Gruyter

     Giuseppe Lippi, Dr Emmanuel J Favaloro

421. 
     Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2015, De Gruyter

     Dr Emmanuel J Favaloro

422. 
     The new and the old of heparin-induced thrombocytopenia

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2015, De Gruyter

     Dr Emmanuel J Favaloro

423. 
     The effect of hyperglycaemia on haemostasis testing - a volunteer study

     Article • Anaesthesia, December 2014, Wiley

     Dr Emmanuel J Favaloro

424. 
     Towards improved diagnosis of von Willebrand disease: Comparative evaluations of several automated von Willebrand factor antigen and activity assays

     Article • Thrombosis Research, December 2014, Elsevier

     Dr Emmanuel J Favaloro

425. 
     Evaluating the interaction of von Willebrand factor and ADAMTS13 - and perhaps also beyond ADAMTS13

     Article • Thrombosis Research, December 2014, Elsevier

     Dr Emmanuel J Favaloro

426. 
     Urgent monitoring of dabigatran plasma levels: sometimes less is more

     Article • Polish Archives of Internal Medicine, November 2014, Towarzystwo Internistow Polskich/Polish Society of Internal Medicine

     Dr Emmanuel J Favaloro

427. 
     Dedication

     Article • Seminars in Thrombosis and Hemostasis, November 2014, Thieme Publishing Group

     Dr Emmanuel J Favaloro

428. 
     Articles from Seminars in Thrombosis & Hemostasis (STH) Archives: Part II

     Article • Seminars in Thrombosis and Hemostasis, November 2014, Thieme Publishing Group

     Dr Emmanuel J Favaloro

429. 
     A Short History of Thrombosis and Hemostasis: Part II (40th Year Celebratory Issue)

     Article • Seminars in Thrombosis and Hemostasis, November 2014, Thieme Publishing Group

     Dr Emmanuel J Favaloro

430. 
     Hot Topics VI

     Article • Seminars in Thrombosis and Hemostasis, October 2014, Thieme Publishing Group

     Dr Emmanuel J Favaloro

431. 
     2014 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards

     Article • Seminars in Thrombosis and Hemostasis, October 2014, Thieme Publishing Group

     Dr Emmanuel J Favaloro

432. 
     Dangers in the Practice of Defensive Medicine in Hemostasis Testing for Investigation of Bleeding or Thrombosis: Part I—Routine Coagulation Testing

     Article • Seminars in Thrombosis and Hemostasis, October 2014, Thieme Publishing Group

     Dr Emmanuel J Favaloro

433. 
     Sodium citrate blood contamination by K2-ethylenediaminetetraacetic acid (EDTA): impact on routine coagulation testing

     Article • International Journal of Laboratory Hematology, October 2014, Wiley

     Dr Gabriel Lima-Oliveira, Dr Emmanuel J Favaloro

434. 
     Antiphospholipid antibody testing for the antiphospholipid syndrome: a comprehensive practical review including a synopsis of challenges and recent guidelines

     Article • Pathology, October 2014, Elsevier

     Dr Emmanuel J Favaloro

435. 
     Thrombophilia testing in patients taking direct oral anticoagulants. Handle with care

     Article • Diagnosis, September 2014, De Gruyter

     Dr Emmanuel J Favaloro

436. 
     A Review of the Value of D-dimer Testing for Prediction of Recurrent Venous Thromboembolism with Increasing Age

     Article • Seminars in Thrombosis and Hemostasis, August 2014, Thieme Publishing Group

     Dr Emmanuel J Favaloro

437. 
     Aging Hemostasis: Changes to Laboratory Markers of Hemostasis As We Age—A Narrative Review

     Article • Seminars in Thrombosis and Hemostasis, August 2014, Thieme Publishing Group

     Dr Emmanuel J Favaloro

438. 
     Evaluating errors in the laboratory identification of von Willebrand disease in the real world

     Article • Thrombosis Research, August 2014, Elsevier

     Dr Emmanuel J Favaloro

439. 
     Comparative sensitivity of commercially available aPTT reagents to mulga snake (Pseudechis australis) venom

     Article • Pathology, August 2014, Elsevier

     Dr Emmanuel J Favaloro

440. 
     A Short History of Thrombosis and Hemostasis: Part I (40th Year Celebratory Issue)

     Article • Seminars in Thrombosis and Hemostasis, July 2014, Thieme Publishing Group

     Dr Emmanuel J Favaloro

441. 
     Articles from Seminars in Thrombosis & Hemostasis (STH) Archives

     Article • Seminars in Thrombosis and Hemostasis, July 2014, Thieme Publishing Group

     Dr Emmanuel J Favaloro

442. 
     Diagnosing von Willebrand Disease: A Short History of Laboratory Milestones and Innovations, Plus Current Status, Challenges, and Solutions

     Article • Seminars in Thrombosis and Hemostasis, June 2014, Thieme Publishing Group

     Dr Emmanuel J Favaloro

443. 
     Combined Administration of Antibiotics and Direct Oral Anticoagulants: A Renewed Indication for Laboratory Monitoring?

     Article • Seminars in Thrombosis and Hemostasis, June 2014, Thieme Publishing Group

     Dr Emmanuel J Favaloro

444. 
     Response to “Comment on E-Cigarettes and Cardiovascular Risk: Beyond Science and Mysticism”

     Article • Seminars in Thrombosis and Hemostasis, May 2014, Thieme Publishing Group

     Dr Emmanuel J Favaloro

445. 
     2014 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

     Article • Seminars in Thrombosis and Hemostasis, May 2014, Thieme Publishing Group

     Dr Emmanuel J Favaloro

446. 
     Laboratory testing for factor inhibitors

     Article • Haemophilia, April 2014, Wiley

     Dr Emmanuel J Favaloro

447. 
     von Willebrand disease and platelet disorders

     Article • Haemophilia, April 2014, Wiley

     Dr Emmanuel J Favaloro

448. 
     Interference from heterophilic antibodies in D-dimer assessment. A case report

     Article • Blood Coagulation & Fibrinolysis, April 2014, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

449. 
     Influence of centrifuge brake on residual platelet count and routine coagulation tests in citrated plasma

     Article • Blood Coagulation & Fibrinolysis, April 2014, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

450. 
     Artefactual “in-vitro coagulopathy” in a patient with non-Hodgkin lymphoma and lower gastrointestinal bleeding

     Article • The Medical Journal of Australia, March 2014, Australasian Medical Publishing Co. Pty Ltd. (AMPCo)

     Dr Emmanuel J Favaloro

451. 
     Quality in Hemostasis and Thrombosis — Part III

     Article • Seminars in Thrombosis and Hemostasis, February 2014, Thieme Publishing Group

     Dr Emmanuel J Favaloro

452. 
     Standardization and Harmonization of Antiphospholipid Antibody Assays

     Article • Seminars in Thrombosis and Hemostasis, February 2014, Thieme Publishing Group

     Dr Emmanuel J Favaloro

453. 
     External Quality Assessment/Proficiency Testing and Internal Quality Control for the PFA-100 and PFA-200: An Update

     Article • Seminars in Thrombosis and Hemostasis, February 2014, Thieme Publishing Group

     Dr Emmanuel J Favaloro

454. 
     A Tribute to Professor Jerry Koutts, MD (Syd), BS, FRACP, FRCPA (1944–2013)

     Article • Seminars in Thrombosis and Hemostasis, January 2014, Thieme Publishing Group

     Dr Emmanuel J Favaloro

455. 
     Welcome to Seminars in Thrombosis & Hemostasis 2014

     Article • Seminars in Thrombosis and Hemostasis, January 2014, Thieme Publishing Group

     Dr Emmanuel J Favaloro

456. 
     Hot Topics V

     Article • Seminars in Thrombosis and Hemostasis, January 2014, Thieme Publishing Group

     Dr Emmanuel J Favaloro

457. 
     Technological Advances in the Hemostasis Laboratory

     Article • Seminars in Thrombosis and Hemostasis, January 2014, Thieme Publishing Group

     Dr Emmanuel J Favaloro

458. 
     The futility of thrombophilia testing

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2014, De Gruyter

     Dr Emmanuel J Favaloro

459. 
     von Willebrand Disease

     Article • January 2014, Elsevier

     Dr Emmanuel J Favaloro

460. 
     E-Cigarettes and Cardiovascular Risk: Beyond Science and Mysticism

     Article • Seminars in Thrombosis and Hemostasis, December 2013, Thieme Publishing Group

     Dr Emmanuel J Favaloro

461. 
     Problems and Solutions in Laboratory Testing for Hemophilia

     Article • Seminars in Thrombosis and Hemostasis, November 2013, Thieme Publishing Group

     Dr Emmanuel J Favaloro

462. 
     Editorial

     Article • Seminars in Thrombosis and Hemostasis, October 2013, Thieme Publishing Group

     Dr Emmanuel J Favaloro

463. 
     Technical Evaluation of the Novel Preanalytical Module on Instrumentation Laboratory ACL TOP: Advancing Automation in Hemostasis Testing

     Article • SLAS TECHNOLOGY, October 2013, Elsevier

     Dr Emmanuel J Favaloro

464. 
     Problems and Solutions in Laboratory Testing for Hemophilia

     Article • Seminars in Thrombosis and Hemostasis, September 2013, Thieme Publishing Group

     Dr Emmanuel J Favaloro

465. 
     Influence of Residual Platelet Count on Routine Coagulation, Factor VIII, and Factor IX Testing in Postfreeze-Thaw Samples

     Article • Seminars in Thrombosis and Hemostasis, September 2013, Thieme Publishing Group

     Dr Emmanuel J Favaloro

466. 
     Sample collection and platelet function testing

     Article • Blood Coagulation & Fibrinolysis, September 2013, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

467. 
     Lupus anticoagulant testing – sometimes mixing is required

     Article • Blood Coagulation & Fibrinolysis, September 2013, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

468. 
     Still more discussion on the journal impact factor

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), August 2013, De Gruyter

     Dr Emmanuel J Favaloro

469. 
     2013 Eberhard F. Mammen Award Announcements

     Article • Seminars in Thrombosis and Hemostasis, August 2013, Thieme Publishing Group

     Dr Emmanuel J Favaloro

470. 
     Laboratory testing for the new oral anticoagulants: a review of current practice

     Article • Pathology, June 2013, Elsevier

     Dr Emmanuel J Favaloro

471. 
     Venous Thrombosis Associated with HMG-CoA Reductase Inhibitors

     Article • Seminars in Thrombosis and Hemostasis, April 2013, Thieme Publishing Group

     Dr Emmanuel J Favaloro

472. 
     Variability and diagnostic utility of antiphospholipid antibodies including lupus anticoagulants

     Article • International Journal of Laboratory Hematology, April 2013, Wiley

     Dr Emmanuel J Favaloro

473. 
     Quality in Hemostasis and Thrombosis, Part II

     Article • Seminars in Thrombosis and Hemostasis, March 2013, Thieme Publishing Group

     Dr Emmanuel J Favaloro

474. 
     Regulation in Hemostasis and Thrombosis: Part I—In Vitro Diagnostics

     Article • Seminars in Thrombosis and Hemostasis, March 2013, Thieme Publishing Group

     Dr Emmanuel J Favaloro

475. 
     Laboratory Evaluation of Von Willebrand Disease: Phenotypic Analysis

     Article • February 2013, Wiley

     Dr Emmanuel J Favaloro

476. 
     Causes of Errors in Medical Laboratories

     Article • February 2013, Wiley

     Dr Emmanuel J Favaloro

477. 
     External Quality Assessment of Factor VIII Inhibitor Assays

     Article • Seminars in Thrombosis and Hemostasis, February 2013, Thieme Publishing Group

     Dr Emmanuel J Favaloro

478. 
     Hot Topics IV

     Article • Seminars in Thrombosis and Hemostasis, February 2013, Thieme Publishing Group

     Dr Emmanuel J Favaloro

479. 
     Trials and tribulations in lupus anticoagulant testing

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2013, De Gruyter

     Dr Emmanuel J Favaloro

480. 
     Article downloads and citations: Is there any relationship?

     Article • Clinica Chimica Acta, January 2013, Elsevier

     Dr Emmanuel J Favaloro

481. 
     Welcome to Seminars in Thrombosis & Hemostasis 2013

     Article • Seminars in Thrombosis and Hemostasis, December 2012, Thieme Publishing Group

     Dr Emmanuel J Favaloro

482. 
     Interference in Coagulation Testing: Focus on Spurious Hemolysis, Icterus, and Lipemia

     Article • Seminars in Thrombosis and Hemostasis, December 2012, Thieme Publishing Group

     Dr Emmanuel J Favaloro

483. 
     Time for a conceptual shift in assessment of internal quality control for whole blood or cell-based testing systems? An evaluation using platelet function and the PFA-100 as a case example

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), November 2012, De Gruyter

     Dr Emmanuel J Favaloro

484. 
     Establishment and characterization of a new and stable collagen‐binding assay for the assessment of von Willebrand factor activity

     Article • International Journal of Laboratory Hematology, October 2012, Wiley

     Dr Emmanuel J Favaloro

485. 
     Massive Posttraumatic Bleeding: Epidemiology, Causes, Clinical Features, and Therapeutic Management

     Article • Seminars in Thrombosis and Hemostasis, October 2012, Thieme Publishing Group

     Dr Emmanuel J Favaloro

486. 
     Novel and Emerging Therapies: Thrombus-Targeted Fibrinolysis

     Article • Seminars in Thrombosis and Hemostasis, October 2012, Thieme Publishing Group

     Dr Emmanuel J Favaloro

487. 
     Quality in Hemostasis and Thrombosis—Part I

     Article • Seminars in Thrombosis and Hemostasis, September 2012, Thieme Publishing Group

     Dr Emmanuel J Favaloro

488. 
     Discard tube for coagulation testing

     Article • Blood Coagulation & Fibrinolysis, September 2012, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

489. 
     New developments in the diagnosis and treatment of von Willebrand disease

     Article • Clinical Investigation, August 2012, OMICS Publishing Group

     Dr Emmanuel J Favaloro

490. 
     ABO blood group, hypercoagulability, and cardiovascular and cancer risk

     Article • Critical Reviews in Clinical Laboratory Sciences, August 2012, Taylor & Francis

     Dr Emmanuel J Favaloro

491. 
     Laboratory hemostasis: milestones in Clinical Chemistry and Laboratory Medicine

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), July 2012, De Gruyter

     Dr Emmanuel J Favaloro

492. 
     In Vitro and In Vivo Hemolysis

     Article • July 2012, De Gruyter

     Dr Emmanuel J Favaloro

493. 
     Thrombotic and Hemorrhagic Syndromes Associated with Autoimmunity and Infection

     Article • Seminars in Thrombosis and Hemostasis, July 2012, Thieme Publishing Group

     ANTONIO COPPOLA, Dr Emmanuel J Favaloro

494. 
     2012 Eberhard F. Mammen Award Announcements

     Article • Seminars in Thrombosis and Hemostasis, July 2012, Thieme Publishing Group

     Dr Emmanuel J Favaloro

495. 
     Different bleeding risk in type 2A and 2M von Willebrand disease: a 2‐year prospective study in 107 patients: a rebuttal

     Article • Journal of Thrombosis and Haemostasis, July 2012, Elsevier

     Dr Emmanuel J Favaloro

496. 
     External Quality Assurance for Heparin Monitoring

     Article • Seminars in Thrombosis and Hemostasis, June 2012, Thieme Publishing Group

     Dr Emmanuel J Favaloro

497. 
     Acquired Inhibitors of Coagulation Factors: Part I—Acquired Hemophilia A

     Article • Seminars in Thrombosis and Hemostasis, June 2012, Thieme Publishing Group

     ANTONIO COPPOLA, Dr Emmanuel J Favaloro

498. 
     Acquired Inhibitors of Coagulation Factors: Part II

     Article • Seminars in Thrombosis and Hemostasis, June 2012, Thieme Publishing Group

     Dr Emmanuel J Favaloro

499. 
     Acquired Functional Coagulation Inhibitors: Review on Epidemiology, Results of a Wet-Workshop on Laboratory Detection, and Implications for Quality of Inhibitor Diagnosis

     Article • Seminars in Thrombosis and Hemostasis, June 2012, Thieme Publishing Group

     Dr Emmanuel J Favaloro

500. 
     Difficulties and pitfalls in the laboratory diagnosis of bleeding disorders

     Article • Haemophilia, June 2012, Wiley

     Dr Emmanuel J Favaloro

501. 
     Quality Standards for Sample Processing, Transportation, and Storage in Hemostasis Testing

     Article • Seminars in Thrombosis and Hemostasis, June 2012, Thieme Publishing Group

     Dr Emmanuel J Favaloro

502. 
     Quality Standards for Sample Collection in Coagulation Testing

     Article • Seminars in Thrombosis and Hemostasis, June 2012, Thieme Publishing Group

     Dr Emmanuel J Favaloro, Dr Gabriel Lima-Oliveira

503. 
     Patient Safety and Quality in Laboratory and Hemostasis Testing: A Renewed Loop?

     Article • Seminars in Thrombosis and Hemostasis, June 2012, Thieme Publishing Group

     Dr Emmanuel J Favaloro

504. 
     Laboratory identification of factor inhibitors: an update

     Article • Pathology, June 2012, Elsevier

     Dr Emmanuel J Favaloro

505. 
     Differential sensitivity of von Willebrand factor (VWF) ‘activity’ assays to large and small VWF molecular weight forms: a cross‐laboratory study comparing ristocetin cofactor, collagen‐binding and mAb‐based assays

     Article • Journal of Thrombosis and Haemostasis, June 2012, Elsevier

     Dr Emmanuel J Favaloro

506. 
     Paradoxical thrombosis part 1: factor replacement therapy, inherited clotting factor deficiencies and prolonged APTT

     Article • Journal of Thrombosis and Thrombolysis, May 2012, Springer Science + Business Media

     Dr Emmanuel J Favaloro

507. 
     Paradoxical thrombosis, part 2: anticoagulant and antiplatelet therapy

     Article • Journal of Thrombosis and Thrombolysis, May 2012, Springer Science + Business Media

     Dr Emmanuel J Favaloro

508. 
     The Antiphospholipid Syndrome: Diagnosis, Pathogenesis, Laboratory Testing, and Management

     Article • Seminars in Thrombosis and Hemostasis, May 2012, Thieme Publishing Group

     Dr Emmanuel J Favaloro

509. 
     Internal Quality Control and External Quality Assurance in Testing for Antiphospholipid Antibodies: Part I—Anticardiolipin and Anti-β2-Glycoprotein I Antibodies

     Article • Seminars in Thrombosis and Hemostasis, May 2012, Thieme Publishing Group

     Dr Emmanuel J Favaloro

510. 
     Internal Quality Control and External Quality Assurance in Testing for Antiphospholipid Antibodies: Part II—Lupus Anticoagulant

     Article • Seminars in Thrombosis and Hemostasis, May 2012, Thieme Publishing Group

     Dr Emmanuel J Favaloro

511. 
     Diagnosis of von Willebrand Disease

     Article • April 2012, Wiley

     Dr Emmanuel J Favaloro

512. 
     Evaluating laboratory approaches to the identification of lupus anticoagulants: A diagnostic challenge from the RCPA Haematology QAP

     Article • Pathology, April 2012, Elsevier

     Dr Emmanuel J Favaloro

513. 
     Relationship between short activated partial thromboplastin times, thrombin generation, procoagulant factors and procoagulant phospholipid activity

     Article • Blood Coagulation & Fibrinolysis, April 2012, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

514. 
     Clinical audit of antiphospholipid antibody testing in tertiary practice: towards improved relevance in thrombophilia investigations

     Article • Internal Medicine Journal, April 2012, Wiley

     Dr Emmanuel J Favaloro

515. 
     Biological therapies for von Willebrand disease

     Article • Expert Opinion on Biological Therapy, March 2012, Informa Healthcare

     Dr Emmanuel J Favaloro

516. 
     Coagulopathies and Thrombosis: Usual and Unusual Causes and Associations, Part VI

     Article • Seminars in Thrombosis and Hemostasis, March 2012, Thieme Publishing Group

     Dr Emmanuel J Favaloro

517. 
     Coffee Intake and Cardiovascular Disease: Virtue Does Not Take Center Stage

     Article • Seminars in Thrombosis and Hemostasis, February 2012, Thieme Publishing Group

     Dr Emmanuel J Favaloro

518. 
     Hemostatic Properties of the Lymph: Relationships with Occlusion and Thrombosis

     Article • Seminars in Thrombosis and Hemostasis, February 2012, Thieme Publishing Group

     Dr Emmanuel J Favaloro

519. 
     Hot Topics III

     Article • Seminars in Thrombosis and Hemostasis, February 2012, Thieme Publishing Group

     Dr Emmanuel J Favaloro

520. 
     Welcome to Seminars in Thrombosis & Hemostasis 2012

     Article • Seminars in Thrombosis and Hemostasis, February 2012, Thieme Publishing Group

     Dr Emmanuel J Favaloro

521. 
     2B or not 2B? Masquerading as von Willebrand disease?

     Article • Journal of Thrombosis and Haemostasis, February 2012, Elsevier

     Dr Emmanuel J Favaloro

522. 
     Pre-analytical Variables in Coagulation Testing Associated With Diagnostic Errors in Hemostasis

     Article • Laboratory Medicine, February 2012, Oxford University Press (OUP)

     Dr Emmanuel J Favaloro

523. 
     The new oral anticoagulants and the future of haemostasis laboratory testing

     Article • Biochemia Medica, January 2012, Croatian Society for Medical Biochemistry and Laboratory Medicine

     Dr Emmanuel J Favaloro

524. 
     Proficiency testing/external quality assurance for the PFA-100®

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2012, De Gruyter

     Dr Emmanuel J Favaloro

525. 
     Influence of mechanical trauma of blood and hemolysis on PFA-100 testing

     Article • Blood Coagulation & Fibrinolysis, January 2012, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

526. 
     Biomedical research platforms and their influence on article submissions and journal rankings: An update

     Article • Biochemia Medica, January 2012, Croatian Society for Medical Biochemistry and Laboratory Medicine

     Dr Emmanuel J Favaloro

527. 
     Standards and reference materials for the anticardiolipin and anti-β2glycoprotein I assays: A report of recommendations from the APL Task Force at the 13th International Congress on Antiphospholipid Antibodies

     Article • Clinica Chimica Acta, January 2012, Elsevier

     Dr Emmanuel J Favaloro

528. 
     A novel flow cytometry single tube bead assay for quantitation of von Willebrand factor antigen and collagen-binding

     Article • Thrombosis and Haemostasis, January 2012, Thieme Publishing Group

     Dr Emmanuel J Favaloro

529. 
     International consensus guidelines on anticardiolipin and anti–β 2 ‐glycoprotein I testing: Report from the 13th International Congress on Antiphospholipid Antibodies

     Article • Arthritis & Rheumatism, December 2011, Wiley

     Dr Emmanuel J Favaloro

530. 
     Antisense therapy in the treatment of hypercholesterolemia

     Article • European Journal of Internal Medicine, December 2011, Elsevier

     Dr Emmanuel J Favaloro

531. 
     Laboratory testing of anticoagulants: the present and the future

     Article • Pathology, December 2011, Elsevier

     Dr Emmanuel J Favaloro

532. 
     A robust method for testing urinary iodine using a microtitre robotic system

     Article • Journal of Trace Elements in Medicine and Biology, December 2011, Elsevier

     Dr Emmanuel J Favaloro

533. 
     Iodine Deficiency: Current Aspects and Future Prospects

     Article • Laboratory Medicine, December 2011, Oxford University Press (OUP)

     Dr Emmanuel J Favaloro

534. 
     Direct-to-consumer testing: more risks than opportunities

     Article • International Journal of Clinical Practice, November 2011, Hindawi Publishing Corporation

     Dr Emmanuel J Favaloro

535. 
     Holiday Thrombosis

     Article • Seminars in Thrombosis and Hemostasis, November 2011, Thieme Publishing Group

     Dr Emmanuel J Favaloro

536. 
     Seminars in Thrombosis & Hemostasis 2010: Impact Factor and Highest-Cited Articles from 2008 to 2009

     Article • Seminars in Thrombosis and Hemostasis, November 2011, Thieme Publishing Group

     Dr Emmanuel J Favaloro

537. 
     Coagulopathies and Thrombosis: Usual and Unusual Causes and Associations. Part V.

     Article • Seminars in Thrombosis and Hemostasis, November 2011, Thieme Publishing Group

     Dr Emmanuel J Favaloro

538. 
     Diagnosis and classification of von Willebrand disease

     Article • Blood Coagulation & Fibrinolysis, October 2011, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

539. 
     von Willebrand Factor Assay Proficiency Testing Continued

     Article • American Journal of Clinical Pathology, September 2011, Oxford University Press (OUP)

     Dr Emmanuel J Favaloro

540. 
     Thrombocytopenic Platelet Disorders

     Article • Seminars in Thrombosis and Hemostasis, September 2011, Thieme Publishing Group

     Dr Emmanuel J Favaloro

541. 
     Diagnosis of type 1 vs. 2A and 2M von Willebrand disease

     Article • Haemophilia, August 2011, Wiley

     Dr Emmanuel J Favaloro

542. 
     Cycling: To Race or to Live – Reflections on Skewed Priorities?

     Article • International Journal of Sports Medicine, August 2011, Thieme Publishing Group

     Dr Emmanuel J Favaloro

543. 
     Distinguishing types 1 and 2M von Willebrand disease

     Article • International Journal of Laboratory Hematology, July 2011, Wiley

     Dr Emmanuel J Favaloro

544. 
     Diagnosis and Management of v on Willebrand Disease in Australia

     Article • Seminars in Thrombosis and Hemostasis, July 2011, Thieme Publishing Group

     Dr Emmanuel J Favaloro

545. 
     von Willebrand Disease: Local Diagnosis and Management of a Globally Distributed Bleeding Disorder

     Article • Seminars in Thrombosis and Hemostasis, July 2011, Thieme Publishing Group

     Dr Emmanuel J Favaloro

546. 
     2011 Eberhard F. Mammen Award Announcements

     Article • Seminars in Thrombosis and Hemostasis, July 2011, Thieme Publishing Group

     Dr Emmanuel J Favaloro

547. 
     Michael Dawson, B. Pharm. (Hon), Ph.D. (1954–2010)

     Article • Seminars in Thrombosis and Hemostasis, July 2011, Thieme Publishing Group

     Dr Emmanuel J Favaloro

548. 
     v on Willebrand Disease: Local Diagnosis and Management of a Globally Distributed Bleeding Disorder

     Article • Seminars in Thrombosis and Hemostasis, July 2011, Thieme Publishing Group

     Dr Emmanuel J Favaloro

549. 
     Assessment for antithrombin deficiency in the real world

     Article • International Journal of Laboratory Hematology, June 2011, Wiley

     Dr Emmanuel J Favaloro

550. 
     Regulation of in vitro diagnostics (IVDs) for use in Australian pathology laboratories: a gloomy outlook for future pathology testing in this country?

     Article • Pathology, June 2011, Elsevier

     Dr Emmanuel J Favaloro

551. 
     Inherited disorders of blood coagulation

     Article • Annals of Medicine, May 2011, Taylor & Francis

     Dr Emmanuel J Favaloro

552. 
     Laboratory testing and/or monitoring of the new oral anticoagulants/antithrombotics: for and against?

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), May 2011, De Gruyter

     Dr Emmanuel J Favaloro

553. 
     Laboratory diagnostics and appropriate care of people with haemophilia

     Article • Haemophilia, April 2011, Wiley

     Dr Emmanuel J Favaloro

554. 
     Inherited and acquired factor V deficiency

     Article • Blood Coagulation & Fibrinolysis, April 2011, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

555. 
     A clinical audit of congenital thrombophilia investigation in tertiary practice

     Article • Pathology, April 2011, Elsevier

     Dr Emmanuel J Favaloro

556. 
     External quality assurance for the PFA‐100®

     Article • Journal of Thrombosis and Haemostasis, April 2011, Elsevier

     Dr Emmanuel J Favaloro

557. 
     Prevention of Venous Thromboembolism: Focus on Mechanical Prophylaxis

     Article • Seminars in Thrombosis and Hemostasis, March 2011, Thieme Publishing Group

     Dr Emmanuel J Favaloro

558. 
     Coagulopathies and Thrombosis: Usual and Unusual Causes and Associations, Part IV

     Article • Seminars in Thrombosis and Hemostasis, March 2011, Thieme Publishing Group

     Dr Emmanuel J Favaloro

559. 
     Obstructive Sleep Apnea Syndrome and Cardiovascular Diseases

     Article • Seminars in Thrombosis and Hemostasis, March 2011, Thieme Publishing Group

     Dr Emmanuel J Favaloro

560. 
     Laboratory Diagnosis of von Willebrand Disease: The Phenotype

     Article • March 2011, Wiley

     Dr Emmanuel J Favaloro

561. 
     Frequency of Platelet type versus Type 2B von Willebrand Disease

     Article • Thrombosis and Haemostasis, February 2011, Schattauer GmbH

     Dr Margareth Castro Ozelo, Dr Emmanuel J Favaloro

562. 
     Venous Thromboembolism in Chronic Liver Disease

     Article • Seminars in Thrombosis and Hemostasis, February 2011, Thieme Publishing Group

     Dr Emmanuel J Favaloro

563. 
     Glycoprotein IIb/IIIa inhibitors: an update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy

     Article • Biomarkers in Medicine, February 2011, Future Medicine

     Dr Emmanuel J Favaloro

564. 
     Functional analysis of three recombinant A1-VWF domain mutants in comparison to wild type and plasma-derived VWF facilitates subtyping in type 2 von Willebrand disease

     Article • Thrombosis Research, February 2011, Elsevier

     Dr Emmanuel J Favaloro

565. 
     ‘Criteria’ aPL tests: Report of a Task Force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010

     Article • Lupus, February 2011, SAGE Publications

     Dr Emmanuel J Favaloro

566. 
     More on preanalytical variables affecting platelet function testing using light transmittance aggregometry

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2011, De Gruyter

     Dr Emmanuel J Favaloro

567. 
     Laboratory testing for the antiphospholipid syndrome: making sense of antiphospholipid antibody assays

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2011, De Gruyter

     Dr Emmanuel J Favaloro

568. 
     Hormones, Endocrine Disorders, and Hemostasis

     Article • Seminars in Thrombosis and Hemostasis, January 2011, Thieme Publishing Group

     Dr Emmanuel J Favaloro

569. 
     The Spectrum of Coagulation Abnormalities in Thyroid Disorders

     Article • Seminars in Thrombosis and Hemostasis, January 2011, Thieme Publishing Group

     Dr Emmanuel J Favaloro

570. 
     Rethinking the diagnosis of von Willebrand disease

     Article • Thrombosis Research, January 2011, Elsevier

     Dr Emmanuel J Favaloro

571. 
     Coagulation update: What's new in hemostasis testing?

     Article • Thrombosis Research, January 2011, Elsevier

     Dr Emmanuel J Favaloro

572. 
     Regulation of in vitro diagnostics (IVDs) for use in clinical diagnostic laboratories: towards the light or dark in clinical laboratory testing?

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2011, De Gruyter

     Dr Emmanuel J Favaloro

573. 
     Interaction of factor VIII and von Willebrand factor and the identification of type 2N von Willebrand disease

     Article • Thrombosis Research, January 2011, Elsevier

     Dr Emmanuel J Favaloro

574. 
     Studies on in vitro hemolysis and utility of corrective formulas for reporting results on hemolyzed specimens

     Article • Biochemia Medica, January 2011, Croatian Society for Medical Biochemistry and Laboratory Medicine

     Dr Emmanuel J Favaloro

575. 
     Laboratory diagnosis of von Willebrand disease: results from a prospective and blind study in 32 laboratories worldwide using lyophilized plasmas

     Article • Journal of Thrombosis and Haemostasis, January 2011, Elsevier

     Dr Emmanuel J Favaloro

576. 
     Laboratory investigation of lupus anticoagulants: mixing studies are sometimes required

     Article • Journal of Thrombosis and Haemostasis, December 2010, Elsevier

     Dr Emmanuel J Favaloro

577. 
     Validation of improved performance characteristics for the automated von Willebrand factor ristocetin cofactor activity assay

     Article • Journal of Thrombosis and Haemostasis, December 2010, Elsevier

     Dr Emmanuel J Favaloro

578. 
     Farewell to 2010!

     Article • Seminars in Thrombosis and Hemostasis, November 2010, Thieme Publishing Group

     Dr Emmanuel J Favaloro

579. 
     Discard Tubes Are Sometimes Necessary When Drawing Samples for HemostasisThe Authors’ Reply

     Article • American Journal of Clinical Pathology, November 2010, Oxford University Press (OUP)

     Dr Emmanuel J Favaloro

580. 
     Article • Seminars in Thrombosis and Hemostasis, November 2010, Thieme Publishing Group

     Dr Emmanuel J Favaloro

581. 
     Global Hemostasis: New Approaches to Patient Diagnosis and Treatment Monitoring

     Article • Seminars in Thrombosis and Hemostasis, October 2010, Thieme Publishing Group

     Dr Emmanuel J Favaloro

582. 
     Winners of the 2010 Eberhard F. Mammen Award for Most Popular Article during 2008–2009

     Article • Seminars in Thrombosis and Hemostasis, October 2010, Thieme Publishing Group

     Dr Emmanuel J Favaloro

583. 
     Hemolytic Uremic Syndrome

     Article • Seminars in Thrombosis and Hemostasis, September 2010, Thieme Publishing Group

     Dr Emmanuel J Favaloro

584. 
     C-reactive protein and venous thromboembolism: causal or casual association?

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), August 2010, De Gruyter

     Dr Emmanuel J Favaloro

585. 
     Recombinants in Thrombosis and Hemostasis: From Basic Research to Clinical Therapy

     Article • Seminars in Thrombosis and Hemostasis, July 2010, Thieme Publishing Group

     Dr Emmanuel J Favaloro

586. 
     Recombinant Platelet Factor 4: A Therapeutic, Anti-Neoplastic Chimera?

     Article • Seminars in Thrombosis and Hemostasis, July 2010, Thieme Publishing Group

     Dr Emmanuel J Favaloro

587. 
     2009 Eberhard F. Mammen Young Investigator Award Winners

     Article • Seminars in Thrombosis and Hemostasis, July 2010, Thieme Publishing Group

     Dr Emmanuel J Favaloro

588. 
     Thrombotic Complications of Erythropoiesis-Stimulating Agents

     Article • Seminars in Thrombosis and Hemostasis, July 2010, Thieme Publishing Group

     Dr Emmanuel J Favaloro

589. 
     Shortened activated partial thromboplastin time: causes and management

     Article • Blood Coagulation & Fibrinolysis, July 2010, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

590. 
     Quality issues in laboratory haemostasis

     Article • Haemophilia, June 2010, Wiley

     Dr Emmanuel J Favaloro

591. 
     Laboratory identification of factor VIII inhibitors in the real world: the experience from Australasia

     Article • Haemophilia, June 2010, Wiley

     Dr Emmanuel J Favaloro

592. 
     Laboratory Testing in Disseminated Intravascular Coagulation

     Article • Seminars in Thrombosis and Hemostasis, June 2010, Thieme Publishing Group

     Dr Emmanuel J Favaloro

593. 
     Laboratory testing in pharmacies

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), May 2010, De Gruyter

     Dr Emmanuel J Favaloro

594. 
     Improving the harmonisation of the International Normalized Ratio (INR): time to think outside the box?

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), May 2010, De Gruyter

     Dr Emmanuel J Favaloro

595. 
     UNSUSPECTED COAGULOPATHY RARELY PREVENTS IV THROMBOLYSIS IN ACUTE ISCHEMIC STROKE

     Article • Neurology, May 2010, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

596. 
     Laboratory medicine and natural disasters: are we ready for the challenge?

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), May 2010, De Gruyter

     Dr Emmanuel J Favaloro

597. 
     The antiphospholipid syndrome: a large elephant with many parts or an elusive chameleon disguised by many colours?

     Article • Autoimmunity Highlights, May 2010, Springer Science + Business Media

     Dr Emmanuel J Favaloro

598. 
     Problems in laboratory testing: hemophilia and beyond

     Article • Journal of Thrombosis and Haemostasis, May 2010, Elsevier

     Dr Emmanuel J Favaloro

599. 
     Under-Recognized Significance of Endothelial Heterogeneity: Hemostasis, Thrombosis, and Beyond

     Article • Seminars in Thrombosis and Hemostasis, April 2010, Thieme Publishing Group

     Dr Emmanuel J Favaloro

600. 
     Proteomic analysis of venous thromboembolism

     Article • Expert Review of Proteomics, April 2010, Taylor & Francis

     Dr Emmanuel J Favaloro

601. 
     Genetic testing in von Willebrand disease: reply to rebuttal

     Article • Journal of Thrombosis and Haemostasis, April 2010, Elsevier

     Dr Emmanuel J Favaloro

602. 
     Prevalence of hypokalaemia: the experience of a large academic hospital

     Article • Internal Medicine Journal, April 2010, Wiley

     Dr Emmanuel J Favaloro

603. 
     Biochemical markers for the diagnosis of venous thromboembolism: the past, present and future

     Article • Journal of Thrombosis and Thrombolysis, March 2010, Springer Science + Business Media

     Dr Emmanuel J Favaloro

604. 
     Platelets, Inflammation and Cardiovascular Diseases. New Concepts and Therapeutic Implications

     Article • Seminars in Thrombosis and Hemostasis, March 2010, Thieme Publishing Group

     Dr Emmanuel J Favaloro

605. 
     A laboratory evaluation into the short activated partial thromboplastin time

     Article • Blood Coagulation & Fibrinolysis, March 2010, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

606. 
     Mild hemophilia A

     Article • Journal of Thrombosis and Haemostasis, March 2010, Elsevier

     Dr Emmanuel J Favaloro

607. 
     Contemporary platelet function testing

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), February 2010, De Gruyter

     Dr Emmanuel J Favaloro

608. 
     Coagulopathies and Thrombosis: Usual and Unusual Causes and Associations, Part III

     Article • Seminars in Thrombosis and Hemostasis, February 2010, Thieme Publishing Group

     Dr Emmanuel J Favaloro

609. 
     Influenza and Cardiovascular Disease: Does Swine-Origin, 2009 H1N1 Flu Virus Represent a Risk Factor, an Acute Trigger, or Both?

     Article • Seminars in Thrombosis and Hemostasis, February 2010, Thieme Publishing Group

     Dr Emmanuel J Favaloro

610. 
     Moderate Red Wine Consumption and Cardiovascular Disease Risk: Beyond the “French Paradox”

     Article • Seminars in Thrombosis and Hemostasis, February 2010, Thieme Publishing Group

     Dr Emmanuel J Favaloro

611. 
     Right or wrong sample received for coagulation testing? Tentative algorithms for detection of an incorrect type of sample

     Article • International Journal of Laboratory Hematology, February 2010, Wiley

     Dr Emmanuel J Favaloro

612. 
     Quality in coagulation and haemostasis testing

     Article • Biochemia Medica, January 2010, Croatian Society for Medical Biochemistry and Laboratory Medicine

     Dr Emmanuel J Favaloro

613. 
     Hemophilia, cancer and cardiovascular disease

     Article • Blood Coagulation & Fibrinolysis, January 2010, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

614. 
     Glanzmann thrombasthenia: An update

     Article • Clinica Chimica Acta, January 2010, Elsevier

     Dr Emmanuel J Favaloro

615. 
     Genetic testing for von Willebrand disease: the case against

     Article • Journal of Thrombosis and Haemostasis, January 2010, Elsevier

     Dr Emmanuel J Favaloro

616. 
     Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease

     Article • Thrombosis and Haemostasis, January 2010, Thieme Publishing Group

     Dr Emmanuel J Favaloro

617. 
     Laboratory reporting of hemostasis assays: the final post-analytical opportunity to reduce errors of clinical diagnosis in hemostasis?

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), December 2009, De Gruyter

     Dr Emmanuel J Favaloro

618. 
     Identification and prevalence of von Willebrand disease type 2N (Normandy) in Australia

     Article • Blood Coagulation & Fibrinolysis, December 2009, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

619. 
     Current clinical and laboratory practice for the investigation of the antiphospholipid syndrome: findings from the 2008 Australasian antiphospholipid antibody survey

     Article • Pathology, December 2009, Elsevier

     Dr Emmanuel J Favaloro

620. 
     Emanuele Favaloro (1920–2009) and Francesca Favaloro (1922–2009)

     Article • Seminars in Thrombosis and Hemostasis, November 2009, Thieme Publishing Group

     Dr Emmanuel J Favaloro

621. 
     Farewell to 2009!

     Article • Seminars in Thrombosis and Hemostasis, November 2009, Thieme Publishing Group

     Dr Emmanuel J Favaloro

622. 
     Identification, Pathogenesis, and Treatment of Factor Inhibitors

     Article • Seminars in Thrombosis and Hemostasis, November 2009, Thieme Publishing Group

     Dr Emmanuel J Favaloro

623. 
     Investigations from External Quality Assurance Programs Reveal a High Degree of Variation in the Laboratory Identification of Coagulation Factor Inhibitors

     Article • Seminars in Thrombosis and Hemostasis, November 2009, Thieme Publishing Group

     Dr Emmanuel J Favaloro

624. 
     Winners of the Inaugural Eberhard F. Mammen Award for Most Popular Article

     Article • Seminars in Thrombosis and Hemostasis, October 2009, Thieme Publishing Group

     Dr Emmanuel J Favaloro

625. 
     Coagulopathies and Thrombosis: Usual and Unusual Causes and Associations, Part II

     Article • Seminars in Thrombosis and Hemostasis, October 2009, Thieme Publishing Group

     Dr Emmanuel J Favaloro

626. 
     Laboratory Investigation of Thrombophilia: The Good, the Bad, and the Ugly

     Article • Seminars in Thrombosis and Hemostasis, October 2009, Thieme Publishing Group

     Dr Emmanuel J Favaloro

627. 
     Unsuspected Triggers of Venous Thromboembolism—Trivial or Not So Trivial?

     Article • Seminars in Thrombosis and Hemostasis, October 2009, Thieme Publishing Group

     Dr Emmanuel J Favaloro

628. 
     Prostate-Specific Antigen, Prostate Cancer, and Disorders of Hemostasis

     Article • Seminars in Thrombosis and Hemostasis, October 2009, Thieme Publishing Group

     Dr Emmanuel J Favaloro

629. 
     The Bidirectional Relationship of Cancer and Hemostasis and the Potential Role of Anticoagulant Therapy in Moderating Thrombosis and Cancer Spread

     Article • Seminars in Thrombosis and Hemostasis, October 2009, Thieme Publishing Group

     Dr Emmanuel J Favaloro

630. 
     Potential supplementary utility of combined PFA-100 and functional von Willebrand factor testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease

     Article • Blood Coagulation & Fibrinolysis, September 2009, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

631. 
     Tirofiban and Activated Protein C Synergistically Inhibit the Instant Blood Mediated Inflammatory Reaction (IBMIR) from Allogeneic Islet Cells Exposure to Human Blood

     Article • American Journal of Transplantation, September 2009, Elsevier

     Dr Emmanuel J Favaloro

632. 
     D-Dimer Measurement and Laboratory Feedback

     Article • Journal of Emergency Medicine, July 2009, Elsevier

     Dr Emmanuel J Favaloro

633. 
     Laboratory assessment and perioperative management of patients on antiplatelet therapy: From the bench to the bedside

     Article • Clinica Chimica Acta, July 2009, Elsevier

     Dr Emmanuel J Favaloro

634. 
     Relationship between 24-h air pollution, emergency department admission and diagnosis of acute coronary syndrome

     Article • Journal of Thrombosis and Thrombolysis, June 2009, Springer Science + Business Media

     Dr Emmanuel J Favaloro

635. 
     Methodology and outcomes of platelet aggregation testing in Australia, New Zealand and the Asia‐Pacific region: results of a survey from the Royal College of Pathologists of Australasia Haematology Quality Assurance Program

     Article • International Journal of Laboratory Hematology, June 2009, Wiley

     Dr Emmanuel J Favaloro

636. 
     The role of ethnicity, age and gender in venous thromboembolism

     Article • Journal of Thrombosis and Thrombolysis, June 2009, Springer Science + Business Media

     Dr Emmanuel J Favaloro

637. 
     Time to seek further clarity in the molecular analysis of von Willebrand disease?

     Article • Thrombosis and Haemostasis, June 2009, Schattauer GmbH

     Dr Emmanuel J Favaloro

638. 
     Rare Bleeding Disorders

     Article • Seminars in Thrombosis and Hemostasis, June 2009, Thieme Publishing Group

     Dr Emmanuel J Favaloro

639. 
     Rodger L. Bick, M.D., Ph.D., FACP (1943–2008)

     Article • Seminars in Thrombosis and Hemostasis, April 2009, Thieme Publishing Group

     Dr Emmanuel J Favaloro

640. 
     Coagulopathies and Thrombosis: Usual and Unusual Causes and Associations, Part I

     Article • Seminars in Thrombosis and Hemostasis, April 2009, Thieme Publishing Group

     Dr Emmanuel J Favaloro

641. 
     Mental Depression and Cardiovascular Disease: A Multifaceted, Bidirectional Association

     Article • Seminars in Thrombosis and Hemostasis, April 2009, Thieme Publishing Group

     Dr Emmanuel J Favaloro

642. 
     Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: Differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?

     Article • Thrombosis Research, April 2009, Elsevier

     Dr Emmanuel J Favaloro

643. 
     Internal Quality Control and External Quality Assurance of Platelet Function Tests

     Article • Seminars in Thrombosis and Hemostasis, March 2009, Thieme Publishing Group

     Dr Emmanuel J Favaloro

644. 
     Diagnostic Evaluation of Platelet Disorders: The Past, the Present, and the Future

     Article • Seminars in Thrombosis and Hemostasis, March 2009, Thieme Publishing Group

     Dr Emmanuel J Favaloro

645. 
     Welcome to the First Issue of Seminars in Thrombosis and Hemostasis for 2009

     Article • Seminars in Thrombosis and Hemostasis, February 2009, Thieme Publishing Group

     Dr Emmanuel J Favaloro

646. 
     Milestones and Perspectives in Coagulation and Hemostasis

     Article • Seminars in Thrombosis and Hemostasis, February 2009, Thieme Publishing Group

     Dr Emmanuel J Favaloro

647. 
     Relationship between activated partial thromboplastin time, heparin and potassium levels

     Article • Diabetes Research and Clinical Practice, February 2009, Elsevier

     Dr Emmanuel J Favaloro

648. 
     Laboratory Diagnostics and Therapy in Thrombosis and Hemostasis: From Bedside to Bench to Bedside

     Article • Seminars in Thrombosis and Hemostasis, February 2009, Thieme Publishing Group

     Dr Emmanuel J Favaloro

649. 
     Toward a New Paradigm for the Identification and Functional Characterization of von Willebrand Disease

     Article • Seminars in Thrombosis and Hemostasis, February 2009, Thieme Publishing Group

     Dr Emmanuel J Favaloro

650. 
     High Rate of Deficiency in the Amino Acids Tryptophan and Histidine in People with Wounds

     Article • Advances in Skin & Wound Care, February 2009, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

651. 
     The missing link between genotype, phenotype and clinics

     Article • Biochemia Medica, January 2009, Croatian Society for Medical Biochemistry and Laboratory Medicine

     Dr Emmanuel J Favaloro

652. 
     Pharmacogenetics of vitamin K antagonists: useful or hype?

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2009, De Gruyter

     Dr Emmanuel J Favaloro

653. 
     The Journal Impact Factor: don't expect its demise any time soon

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2009, De Gruyter

     Dr Emmanuel J Favaloro

654. 
     Diagnosis of von willebrand disease (VWD): towards a new paradigm for the identification and functional characterisation of VWD

     Article • Pathology, January 2009, Elsevier

     Dr Emmanuel J Favaloro

655. 
     One-stage clotting versus chromogenic assays for assessing recombinant factor VIII: two faces of a haemostasis coin

     Article • Blood Coagulation & Fibrinolysis, January 2009, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

656. 
     Survey on the prevalence of hemolytic specimens in an academic hospital according to collection facility: opportunities for quality improvement

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2009, De Gruyter

     Dr Emmanuel J Favaloro

657. 
     Epidemiological association between fasting plasma glucose and shortened APTT

     Article • Clinical Biochemistry, January 2009, Elsevier

     Dr Emmanuel J Favaloro

658. 
     Laboratory Evaluation of von Willebrand Disease: Phenotypic Analysis

     Article • December 2008, Wiley

     Dr Emmanuel J Favaloro

659. 
     Aspirin ‘responsiveness’, ‘nonresponsiveness’ or ‘resistance’: a putative role for von Willebrand factor?

     Article • Blood Coagulation & Fibrinolysis, December 2008, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

660. 
     Welcome to a Special Issue of Seminars in Thrombosis and Hemostasis —The Closing Issue for 2008

     Article • Seminars in Thrombosis and Hemostasis, November 2008, Thieme Publishing Group

     Dr Emmanuel J Favaloro

661. 
     A Tribute to Eberhard F. Mammen, M.D. (1930–2008)

     Article • Seminars in Thrombosis and Hemostasis, November 2008, Thieme Publishing Group

     Dr Emmanuel J Favaloro

662. 
     Clinical Utility of the PFA-100

     Article • Seminars in Thrombosis and Hemostasis, November 2008, Thieme Publishing Group

     Dr Emmanuel J Favaloro

663. 
     Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD): a rebuttal

     Article • Journal of Thrombosis and Haemostasis, November 2008, Elsevier

     Dr Emmanuel J Favaloro

664. 
     Activated Partial Thromboplastin Time: New Tricks for an Old Dogma

     Article • Seminars in Thrombosis and Hemostasis, October 2008, Thieme Publishing Group

     Dr Emmanuel J Favaloro

665. 
     Laboratory Diagnostics in Thrombosis and Hemostasis: The Past, the Present, and the Future

     Article • Seminars in Thrombosis and Hemostasis, October 2008, Thieme Publishing Group

     Dr Emmanuel J Favaloro

666. 
     Standardization of the INR: How Good Is Your Laboratory's INR and Can It Be Improved?

     Article • Seminars in Thrombosis and Hemostasis, October 2008, Thieme Publishing Group

     Dr Emmanuel J Favaloro

667. 
     Preanalytical and Postanalytical Variables: The Leading Causes of Diagnostic Error in Hemostasis?

     Article • Seminars in Thrombosis and Hemostasis, October 2008, Thieme Publishing Group

     Dr Emmanuel J Favaloro

668. 
     Dark chocolate: consumption for pleasure or therapy?

     Article • Journal of Thrombosis and Thrombolysis, September 2008, Springer Science + Business Media

     Dr Emmanuel J Favaloro

669. 
     Hyperthyroidism is associated with shortened APTT and increased fibrinogen values in a general population of unselected outpatients

     Article • Journal of Thrombosis and Thrombolysis, September 2008, Springer Science + Business Media

     Dr Emmanuel J Favaloro

670. 
     Salbutamol in Athletes

     Article • Clinical Journal of Sport Medicine, September 2008, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

671. 
     Genetics of type 2B von Willebrand Disease: “True 2B,” “tricky 2B,” or “Not 2B.” What Are the Modifiers of the Phenotype?

     Article • Seminars in Thrombosis and Hemostasis, September 2008, Thieme Publishing Group

     Dr Emmanuel J Favaloro

672. 
     A better approach to monitoring of therapy in von Willebrand disease?

     Article • Thrombosis and Haemostasis, August 2008, Schattauer GmbH

     Dr Emmanuel J Favaloro

673. 
     Updates on improvement of human athletic performance: focus on world records in athletics

     Article • British Medical Bulletin, August 2008, Oxford University Press (OUP)

     Dr Emmanuel J Favaloro

674. 
     Differential identification of PT‐VWD from type 2B VWD and GP1BA nomenclature issues response to Othman

     Article • British Journal of Haematology, June 2008, Wiley

     Dr Emmanuel J Favaloro

675. 
     The genetic basis of human athletic performance. Why are psychological components so often overlooked?

     Article • The Journal of Physiology, June 2008, Wiley

     Dr Emmanuel J Favaloro

676. 
     Antiphospholipid Antibodies and the Antiphospholipid Syndrome II: Limitations, Standardization, and Clinical Utility of Laboratory Testing

     Article • Seminars in Thrombosis and Hemostasis, June 2008, Thieme Publishing Group

     Dr Emmanuel J Favaloro

677. 
     Laboratory Testing and Identification of Antiphospholipid Antibodies and the Antiphospholipid Syndrome: A Potpourri of Problems, a Compilation of Possible Solutions

     Article • Seminars in Thrombosis and Hemostasis, June 2008, Thieme Publishing Group

     Dr Emmanuel J Favaloro

678. 
     A Consensus Approach to the Formulation of Guidelines for Laboratory Testing and Reporting of Antiphospholipid Antibody Assays

     Article • Seminars in Thrombosis and Hemostasis, June 2008, Thieme Publishing Group

     Dr Emmanuel J Favaloro

679. 
     The paradoxical relationship between serum uric acid and cardiovascular disease

     Article • Clinica Chimica Acta, June 2008, Elsevier

     Dr Emmanuel J Favaloro

680. 
     Article • Seminars in Thrombosis and Hemostasis, June 2008, Thieme Publishing Group

     Dr Emmanuel J Favaloro

681. 
     Cardiac biomarkers in pulmonary embolism

     Article • Thrombosis and Haemostasis, May 2008, Schattauer GmbH

     Dr Emmanuel J Favaloro

682. 
     Stability of coagulation assays performed in plasma from citrated whole blood transported at ambient temperature: Only a part of the story

     Article • Thrombosis and Haemostasis, May 2008, Schattauer GmbH

     Dr Emmanuel J Favaloro

683. 
     Potential benefits of improved protein intake in older people

     Article • Nutrition & Dietetics, May 2008, Wiley

     Dr Emmanuel J Favaloro

684. 
     Clinical Features, Diagnosis, and Management of the Antiphospholipid Syndrome

     Article • Seminars in Thrombosis and Hemostasis, April 2008, Thieme Publishing Group

     Dr Emmanuel J Favaloro

685. 
     Professor Ronald A. Asherson, M.D. (Hon), F.R.C.P., M.D., F.A.C.P., F.C.P., F.A.C.R., Dip. O&G (Hon) [1934–2008]

     Article • Seminars in Thrombosis and Hemostasis, April 2008, Thieme Publishing Group

     Dr Emmanuel J Favaloro

686. 
     Antiphospholipid Antibodies and the Antiphospholipid Syndrome I: Pathogenesis, Clinical Features, Diagnosis, and Management

     Article • Seminars in Thrombosis and Hemostasis, April 2008, Thieme Publishing Group

     Dr Emmanuel J Favaloro

687. 
     The LOC387715 Polymorphism, Inflammatory Markers, Smoking, and Age-Related Macular Degeneration

     Article • Ophthalmology, April 2008, Elsevier

     Dr Emmanuel J Favaloro

688. 
     Time to think outside the box? Prothrombin time, international normalised ratio, international sensitivity index, mean normal prothrombin time and measurement of uncertainty a novel approach to standardisation

     Article • Pathology, April 2008, Elsevier

     Dr Emmanuel J Favaloro

689. 
     Can blood flow assays help to identify clinically relevant differences in von Willebrand factor functionality in von Willebrand disease types 1–3?

     Article • Journal of Thrombosis and Haemostasis, March 2008, Elsevier

     Dr Emmanuel J Favaloro

690. 
     von Willebrand disease, type 2B: A diagnosis more elusive than previously thought

     Article • Thrombosis and Haemostasis, February 2008, Schattauer GmbH

     Dr Emmanuel J Favaloro

691. 
     Welcome to Seminars in Thrombosis and Hemostasis -2008!

     Article • Seminars in Thrombosis and Hemostasis, February 2008, Thieme Publishing Group

     Dr Emmanuel J Favaloro

692. 
     Measuring the Quality of Journals and Journal Articles: The Impact Factor Tells but a Portion of the Story

     Article • Seminars in Thrombosis and Hemostasis, February 2008, Thieme Publishing Group

     Dr Emmanuel J Favaloro

693. 
     Hot Topics II: An Editorial Collection of Current Issues and Controversies in Thrombosis and Hemostasis

     Article • Seminars in Thrombosis and Hemostasis, February 2008, Thieme Publishing Group

     Dr Emmanuel J Favaloro

694. 
     Phenotypic Identification of Platelet-Type von Willebrand Disease and Its Discrimination from Type 2B von Willebrand Disease: A Question of 2B or Not 2B? A Story of Nonidentical Twins? Or Two Sides of a Multidenominational or Multifaceted Primary-Hemos...

     Article • Seminars in Thrombosis and Hemostasis, February 2008, Thieme Publishing Group

     Dr Emmanuel J Favaloro

695. 
     Detection of duplicates and redundancies. A major responsibility of peer-reviewers?

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2008, De Gruyter

     Dr Emmanuel J Favaloro

696. 
     Help me, Doctor! My D-dimer is raised

     Article • Annals of Medicine, January 2008, Taylor & Francis

     Dr Emmanuel J Favaloro

697. 
     Protein Z is reduced in chronic kidney disease and not elevated in patients on haemodialysis

     Article • Blood Coagulation & Fibrinolysis, January 2008, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

698. 
     Air pollution and coagulation testing: A new source of biological variability?

     Article • Thrombosis Research, January 2008, Elsevier

     Dr Emmanuel J Favaloro

699. 
     A practical approach to instrument selection, evaluation, basic financial management and implementation in pathology and research

     Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2008, De Gruyter

     Dr Emmanuel J Favaloro

700. 
     Consensus guidelines on anti-beta 2 glycoprotein I testing and reporting

     Article • Pathology, January 2008, Elsevier

     Dr Emmanuel J Favaloro

701. 
     The Diagnostic Dilemma: Dual Presentations of Clinical Mucosal Bleeding and Venous Thrombosis Associated with the Presence of Thrombophilia Markers and Mild Reduction in von Willebrand Factor

     Article • Laboratory Hematology, December 2007, Carden Jennings Publishing Co.

     Dr Emmanuel J Favaloro

702. 
     Hot Topics I: A Potpourri of Current Issues and Controversies in Thrombosis and Hemostasis

     Article • Seminars in Thrombosis and Hemostasis, November 2007, Thieme Publishing Group

     Dr Emmanuel J Favaloro

703. 
     An Update on the von Willebrand Factor Collagen Binding Assay: 21 Years of Age and Beyond Adolescence but Not Yet a Mature Adult

     Article • Seminars in Thrombosis and Hemostasis, November 2007, Thieme Publishing Group

     Dr Emmanuel J Favaloro

704. 
     Hemostatic Dysfunction Associated with Endocrine Disorders as a Major Risk Factor and Cause of Human Morbidity and Mortality: A Comprehensive Meta-review

     Article • Seminars in Thrombosis and Hemostasis, November 2007, Thieme Publishing Group

     Dr Emmanuel J Favaloro

705. 
     Time to Think Outside the Box? Proposals for a New Approach to Future Pharmacokinetic Studies of von Willebrand Factor Concentrates in People with von Willebrand Disease

     Article • Seminars in Thrombosis and Hemostasis, November 2007, Thieme Publishing Group

     Dr Emmanuel J Favaloro

706. 
     Differential identification of a rare form of platelet‐type (pseudo‐) von Willebrand disease (VWD) from Type 2B VWD using a simplified ristocetin‐induced‐platelet‐agglutination mixing assay and confirmed by genetic analysis

     Article • British Journal of Haematology, October 2007, Wiley

     Dr Emmanuel J Favaloro

707. 
     Mis-identification of factor inhibitors by diagnostic haemostasis laboratories: recognition of pitfalls and elucidation of strategies. A follow up to a large multicentre evaluation

     Article • Pathology, October 2007, Elsevier

     Dr Emmanuel J Favaloro

708. 
     More on the impact factor and thrombosis and haemostasis journals: Benefits and limitations

     Article • Thrombosis and Haemostasis, July 2007, Schattauer GmbH

     Dr Emmanuel J Favaloro

709. 
     2B or not 2B? Disparate discrimination of functional VWF discordance using different assay panels or methodologies may lead to success or failure in the early identification of type 2B VWD

     Article • Thrombosis and Haemostasis, July 2007, Schattauer GmbH

     Dr Emmanuel J Favaloro

710. 
     Utility of the PFA-100 as a screening test of platelet function: an audit of haemostasis laboratories in Australia and New Zealand

     Article • Blood Coagulation & Fibrinolysis, July 2007, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

711. 
     Circulating Inflammatory Markers and Hemostatic Factors in Age-Related Maculopathy: A Population-Based Case–Control Study

     Article • Investigative Ophthalmology & Visual Science, May 2007, Association for Research in Vision and Ophthalmology (ARVO)

     Dr Emmanuel J Favaloro

712. 
     Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study

     Article • Thrombosis and Haemostasis, April 2007, Schattauer GmbH

     Dr Emmanuel J Favaloro

713. 
     Standardization, Quality Assurance, and Emerging Diagnostic Technologies in Hemostasis

     Article • Seminars in Thrombosis and Hemostasis, April 2007, Thieme Publishing Group

     Dr Emmanuel J Favaloro

714. 
     Emerging Technologies and Quality Assurance in Hemostasis: A Review of Findings from the Royal College of Pathologists of Australasia Quality Assurance Program

     Article • Seminars in Thrombosis and Hemostasis, April 2007, Thieme Publishing Group

     Dr Emmanuel J Favaloro

715. 
     Standardization, Regulation, Quality Assurance and Emerging Technologies in Hemostasis: Issues, Controversies, Benefits, and Limitations

     Article • Seminars in Thrombosis and Hemostasis, April 2007, Thieme Publishing Group

     Dr Emmanuel J Favaloro

716. 
     A Review of β 2 -Glycoprotein-I Antibody Testing Results From a Peer-Driven Multilaboratory Quality Assurance Program

     Article • American Journal of Clinical Pathology, March 2007, Oxford University Press (OUP)

     Dr Emmanuel J Favaloro

717. 
     Investigating people with mucocutaneous bleeding suggestive of primary hemostatic defects: a low likelihood of a definitive diagnosis?

     Article • Haematologica, March 2007, Ferrata Storti Foundation (Haematologica)

     Dr Emmanuel J Favaloro

718. 
     Erratum

     Article • British Journal of Haematology, March 2007, Wiley

     Dr Emmanuel J Favaloro

719. 
     Preanalytical variables in coagulation testing

     Article • Blood Coagulation & Fibrinolysis, January 2007, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

720. 
     Thrombophilia and Cerebral Vein Thrombosis

     Article • January 2007, Karger Publishers

     Dr Emmanuel J Favaloro

721. 
     Increased Propensity to Bruising in Red-Haired Females: A Possible Role for von Willebrand Factor?

     Article • Anesthesia & Analgesia, December 2006, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

722. 
     2B or not 2B? Differential identification of type 2B, versus pseudo‐, von Willebrand disease – response to Whalley and Perry

     Article • British Journal of Haematology, November 2006, Wiley

     Dr Emmanuel J Favaloro

723. 
     Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor

     Article • Journal of Thrombosis and Haemostasis, October 2006, Elsevier

     Dr Emmanuel J Favaloro

724. 
     Laboratory Monitoring of Therapy in von Willebrand Disease: Efficacy of the PFA-100 and von Willebrand Factor:Collagen-Binding Activity as Coupled Strategies

     Article • Seminars in Thrombosis and Hemostasis, September 2006, Thieme Publishing Group

     Dr Emmanuel J Favaloro

725. 
     More on: platelet function analyser (PFA)‐100® closure time in the evaluation of platelet disorders and platelet function

     Article • Journal of Thrombosis and Haemostasis, September 2006, Elsevier

     Dr Emmanuel J Favaloro

726. 
     Acquired von Willebrand disease: potential contribution of the VWF:CB to the identification of functionally inhibiting auto‐antibodies to von Willebrand factor

     Article • Journal of Thrombosis and Haemostasis, September 2006, Elsevier

     Dr Emmanuel J Favaloro

727. 
     2B or not 2B? Differential identification of type 2B, versus pseudo‐von Willebrand disease

     Article • British Journal of Haematology, August 2006, Wiley

     Dr Emmanuel J Favaloro

728. 
     Laboratory Identification of von Willebrand Disease: Technical and Scientific Perspectives

     Article • Seminars in Thrombosis and Hemostasis, July 2006, Thieme Publishing Group

     Dr Emmanuel J Favaloro

729. 
     The Utility of the PFA-100 in the Identification of von Willebrand Disease: A Concise Review

     Article • Seminars in Thrombosis and Hemostasis, July 2006, Thieme Publishing Group

     Dr Emmanuel J Favaloro

730. 
     Reducing Errors in Identification of von Willebrand Disease: The Experience of the Royal College of Pathologists of Australasia Quality Assurance Program

     Article • Seminars in Thrombosis and Hemostasis, July 2006, Thieme Publishing Group

     Dr Emmanuel J Favaloro

731. 
     More on ‘universal’versus‘selected’ screening for thrombophilia: the hidden costs of false‐positive diagnosis

     Article • British Journal of Haematology, June 2006, Wiley

     Dr Emmanuel J Favaloro

732. 
     Identification of factor inhibitors by diagnostic haemostasis laboratories. A large multi-centre evaluation

     Article • Thrombosis and Haemostasis, June 2006, Schattauer GmbH

     Dr Emmanuel J Favaloro

733. 
     Unrecognized pellagra masquerading as odynophagia

     Article • Internal Medicine Journal, June 2006, Wiley

     Dr Emmanuel J Favaloro

734. 
     Abstracts from the 24th Annual Scientific Meeting

     Article • Immunology and Cell Biology, June 2006, Wiley

     Dr Emmanuel J Favaloro

735. 
     The reactivity of paired plasma and serum samples are comparable in the anticardiolipin and anti‐β2‐glycoprotein‐1 ELISAs: a rebuttal

     Article • Journal of Thrombosis and Haemostasis, June 2006, Elsevier

     Dr Emmanuel J Favaloro

736. 
     Effect of overnight 4°C storage of whole blood on von Willebrand factor

     Article • Transfusion, May 2006, Wiley

     Dr Emmanuel J Favaloro

737. 
     2B or not 2B? What is the role of VWF in platelet–matrix interactions? And what is the role of the VWF:CB in VWD diagnostics? These are the questions

     Article • Journal of Thrombosis and Haemostasis, April 2006, Elsevier

     Dr Emmanuel J Favaloro

738. 
     Activated protein C resistance: The influence of ABO-blood group, gender and age

     Article • Thrombosis Research, January 2006, Elsevier

     Dr Emmanuel J Favaloro

739. 
     Cold storage of citrated whole blood induces drastic time-dependent losses in factor VIII and von Willebrand factor: potential for misdiagnosis of haemophilia and von Willebrand disease

     Article • Blood Coagulation & Fibrinolysis, January 2006, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

740. 
     Reassessment of ABO Blood Group, Sex, and Age on Laboratory Parameters Used to Diagnose von Willebrand Disorder

     Article • American Journal of Clinical Pathology, December 2005, Oxford University Press (OUP)

     Dr Emmanuel J Favaloro

741. 
     Reassessment of ABO Blood Group, Sex, and Age on Laboratory Parameters Used to Diagnose von Willebrand Disorder

     Article • American Journal of Clinical Pathology, December 2005, Oxford University Press (OUP)

     Dr Emmanuel J Favaloro

742. 
     Cross-laboratory audit of normal reference ranges and assessment of ABO blood group, gender and age on detected levels of plasma coagulation factors

     Article • Blood Coagulation & Fibrinolysis, November 2005, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

743. 
     How Useful is the Monitoring of (Low Molecular Weight) Heparin Therapy by Anti-Xa Assay? A Laboratory Perspective

     Article • Laboratory Hematology, September 2005, Carden Jennings Publishing Co.

     Dr Emmanuel J Favaloro

744. 
     Laboratory Identification of Familial Thrombophilia: Do the Pitfalls Exceed the Benefits? A Reassessment of ABO-Blood Group, Gender,Age, and other Laboratory Parameters on the Potential Influence on a Diagnosis of Protein C, Protein S, and Antithromb

     Article • Laboratory Hematology, September 2005, Carden Jennings Publishing Co.

     Dr Emmanuel J Favaloro

745. 
     A Diet Rich in High-Oleic-Acid Sunflower Oil Favorably Alters Low-Density Lipoprotein Cholesterol, Triglycerides, and Factor VII Coagulant Activity

     Article • Journal of the American Dietetic Association, July 2005, Elsevier

     Dr Emmanuel J Favaloro

746. 
     An international survey of current practice in the laboratory assessment of anticoagulant therapy with heparin

     Article • Pathology, June 2005, Elsevier

     Dr Emmanuel J Favaloro

747. 
     Laboratory Diagnosis of von Willebrand Disorder: Use of Multiple Functional Assays Reduces Diagnostic Error Rates

     Article • Laboratory Hematology, June 2005, Carden Jennings Publishing Co.

     Dr Emmanuel J Favaloro

748. 
     Diagnostic Issues in Thrombophilia: A Laboratory Scientist's View

     Article • Seminars in Thrombosis and Hemostasis, February 2005, Thieme Publishing Group

     Dr Emmanuel J Favaloro

749. 
     External Quality Assurance of DNA Testing for Thrombophilia Mutations

     Article • American Journal of Clinical Pathology, February 2005, Oxford University Press (OUP)

     Dr Emmanuel J Favaloro

750. 
     Development of Consensus Guidelines for Anticardiolipin and Lupus Anticoagulant Testing

     Article • Seminars in Thrombosis and Hemostasis, February 2005, Thieme Publishing Group

     Dr Emmanuel J Favaloro

751. 
     Learning from Peer Assessment: The Role of the External Quality Assurance Multilaboratory Thrombophilia Test Process

     Article • Seminars in Thrombosis and Hemostasis, February 2005, Thieme Publishing Group

     Dr Emmanuel J Favaloro

752. 
     Multilaboratory Testing of Thrombophilia: Current and Past Practice in Australasia as Assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology

     Article • Seminars in Thrombosis and Hemostasis, February 2005, Thieme Publishing Group

     Dr Emmanuel J Favaloro

753. 
     A Multilaboratory Peer Assessment Quality Assurance Program-Based Evaluation of Anticardiolipin Antibody, and beta 2 -Glycoprotein I Antibody Testing

     Article • Seminars in Thrombosis and Hemostasis, February 2005, Thieme Publishing Group

     Dr Emmanuel J Favaloro

754. 
     Is elevated factor VIII a risk factor for venous thromboembolism in Canada?

     Article • Thrombosis and Haemostasis, January 2005, Thieme Publishing Group

     Dr Emmanuel J Favaloro

755. 
     Factor V inhibitors

     Article • Blood Coagulation & Fibrinolysis, December 2004, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

756. 
     Template bleeding time and PFA‐100® have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study of 148 patients – a rebuttal

     Article • Journal of Thrombosis and Haemostasis, December 2004, Elsevier

     Dr Emmanuel J Favaloro

757. 
     Potential Laboratory Misdiagnosis of Hemophilia and von Willebrand Disorder Owing to Cold Activation of Blood Samples for Testing

     Article • American Journal of Clinical Pathology, November 2004, Oxford University Press (OUP)

     Dr Emmanuel J Favaloro

758. 
     Potential Laboratory Misdiagnosis of Hemophilia and von Willebrand Disorder Owing to Cold Activation of Blood Samples for Testing

     Article • American Journal of Clinical Pathology, November 2004, Oxford University Press (OUP)

     Dr Emmanuel J Favaloro

759. 
     Evaluation of primary haemostasis in people with neurofibromatosis type 1

     Article • International Journal of Laboratory Hematology, October 2004, Wiley

     Dr Emmanuel J Favaloro

760. 
     von Willebrand disease: laboratory aspects of diagnosis and treatment

     Article • Haemophilia, October 2004, Wiley

     Dr Emmanuel J Favaloro

761. 
     Laboratory diagnosis of von Willebrand's disorder: quality and diagnostic improvements driven by peer review in a multilaboratory test process

     Article • Haemophilia, April 2004, Wiley

     Dr Emmanuel J Favaloro

762. 
     A multi-centre evaluation of the intra-assay and inter-assay variation of commercial and in-house anti-cardiolipin antibody assays

     Article • Pathology, April 2004, Elsevier

     Dr Emmanuel J Favaloro

763. 
     Consensus guidelines on anti-cardiolipin antibody testing and reporting

     Article • Pathology, February 2004, Elsevier

     Dr Emmanuel J Favaloro

764. 
     Laboratory Diagnosis of von Willebrand Disorder

     Article • American Journal of Clinical Pathology, June 2003, Oxford University Press (OUP)

     Dr Emmanuel J Favaloro

765. 
     Laboratory Diagnosis of von Willebrand Disorder: Current Practice in the Southern Hemisphere

     Article • American Journal of Clinical Pathology, June 2003, Oxford University Press (OUP)

     Dr Emmanuel J Favaloro

766. 
     A duplex issue: (i) time to re‐appraise the diagnosis and classification of von Willebrand disorder, and (ii) clarification of the roles of von Willebrand factor collagen binding and ristocetin cofactor activity assays

     Article • Haemophilia, November 2002, Wiley

     Dr Emmanuel J Favaloro

767. 
     Assessing the Usefulness of Anticardiolipin Antibody Assays

     Article • American Journal of Clinical Pathology, October 2002, Oxford University Press (OUP)

     Dr Emmanuel J Favaloro

768. 
     Clinical application of the PFA-100®

     Article • Current Opinion in Hematology, September 2002, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

769. 
     Identification of von Willebrand Disease Type 2N (Normandy) in Australia

     Article • American Journal of Clinical Pathology, August 2002, Oxford University Press (OUP)

     Dr Emmanuel J Favaloro

770. 
     Treatment of two patients with acquired factor VIII inhibitors using cyclophosphamide and prednisone

     Article • American Journal of Hematology, July 2002, Wiley

     Dr Emmanuel J Favaloro

771. 
     von Willebrand Factor Collagen-Binding (Activity) Assay in the Diagnosis of von Willebrand Disease: A 15-Year Journey

     Article • Seminars in Thrombosis and Hemostasis, January 2002, Thieme Publishing Group

     Dr Emmanuel J Favaloro

772. 
     A 9-year retrospective assessment of laboratory testing for activated protein C resistance: evolution of a novel approach to thrombophilia investigations

     Article • Pathology, January 2002, Elsevier

     Dr Emmanuel J Favaloro

773. 
     Nitric Oxide and Prostacyclin are Released by Cultured Apoptotic Human Umbilical Vein Endothelial Cells Consistent with an Anti-Micro-Thrombotic Potential

     Article • Thrombosis and Haemostasis, January 2002, Thieme Publishing Group

     Dr Emmanuel J Favaloro

774. 
     A Comparative Multi-laboratory Assessment of Three Factor VIII/von Willebrand Factor Concentrates

     Article • Thrombosis and Haemostasis, January 2002, Thieme Publishing Group

     Dr Emmanuel J Favaloro

775. 
     Appropriate laboratory assessment as a critical facet in the proper diagnosis and classification of von Willebrand disorder

     Article • Best Practice & Research Clinical Haematology, June 2001, Elsevier

     Dr Emmanuel J Favaloro

776. 
     Utility of the PFA‐100® for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations

     Article • Haemophilia, March 2001, Wiley

     Dr Emmanuel J Favaloro

777. 
     Laboratory diagnosis of von Willebrand disorder (vWD) and monitoring of DDAVP therapy: efficacy of the PFA‐100® and vWF:CBA as combined diagnostic strategies

     Article • Haemophilia, March 2001, Wiley

     Dr Emmanuel J Favaloro

778. 
     Possibility of potential VWD misdiagnosis or misclassification using LIA technology and due to presence of rheumatoid factor

     Article • American Journal of Hematology, January 2001, Wiley

     Dr Emmanuel J Favaloro

779. 
     Collection and Transport of Samples for Laboratory Testing in von Willebrand’s Disease (VWD): Time for a Reappraisal?

     Article • Thrombosis and Haemostasis, January 2001, Thieme Publishing Group

     Dr Emmanuel J Favaloro

780. 
     Human Endothelial Cells Maintain Anti-Aggregatory Activity for Platelets during Apoptosis

     Article • Thrombosis and Haemostasis, January 2001, Thieme Publishing Group

     Dr Emmanuel J Favaloro

781. 
     Assessment of current diagnostic practice and efficacy in testing for von Willebrand's disorder: results from the second Australasian multi-laboratory survey

     Article • Blood Coagulation & Fibrinolysis, December 2000, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

782. 
     Detection of von Willebrand Disorder and Identification of Qualitative von Willebrand Factor Defects Direct Comparison of Commercial ELISA-Based von Willebrand Factor Activity Options

     Article • American Journal of Clinical Pathology, October 2000, Oxford University Press (OUP)

     Dr Emmanuel J Favaloro

783. 
     Is the activity of VWF increased in type II diabetes mellitus?

     Article • Diabetes Research and Clinical Practice, September 2000, Elsevier

     Dr Emmanuel J Favaloro

784. 
     Sulfatide-Binding Assay for von Willebrand Factor

     Article • Thrombosis Research, April 2000, Elsevier

     Dr Emmanuel J Favaloro

785. 
     Type 2B von Willebrand's disease in thirteen individuals from five unrelated Australian families: Phenotype and genotype correlations

     Article • American Journal of Hematology, April 2000, Wiley

     Dr Emmanuel J Favaloro

786. 
     Possibility of potential VWD misdiagnosis or misclassification using LIA technology and due to presence of rheumatoid factor

     Article • American Journal of Hematology, January 2000, Wiley

     Dr Emmanuel J Favaloro

787. 
     Discrimination of von Willebrands Disease (VWD) Subtypes: Direct Comparison of von Willebrand Factor:Collagen Binding Assay (VWF:CBA) with Monoclonal Antibody (MAB) Based VWF-capture Systems

     Article • Thrombosis and Haemostasis, January 2000, Thieme Publishing Group

     Dr Emmanuel J Favaloro

788. 
     Structure and function of the von Willebrand factor A1 domain: analysis with monoclonal antibodies reveals distinct binding sites involved in recognition of the platelet membrane glycoprotein Ib-IX-V complex and ristocetin-dependent activation

     Article • Blood, January 2000, American Society of Hematology

     Dr Emmanuel J Favaloro

789. 
     Collagen Binding Assay for von Willebrand Factor (VWF:CBA): Detection of von Willebrands Disease (VWD), and Discrimination of VWD Subtypes, Depends on Collagen Source

     Article • Thrombosis and Haemostasis, January 2000, Thieme Publishing Group

     Dr Emmanuel J Favaloro

790. 
     Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrand’s disease

     Article • Blood Reviews, December 1999, Elsevier

     Dr Emmanuel J Favaloro

791. 
     Use of a novel platelet function analyzer (PFA‐100™) with high sensitivity to disturbances in von willebrand factor to screen for von willebrand's disease and other disorders

     Article • American Journal of Hematology, November 1999, Wiley

     Dr Emmanuel J Favaloro

792. 
     Use of a novel platelet function analyzer (PFA-100?) with high sensitivity to disturbances in von willebrand factor to screen for von willebrand's disease and other disorders

     Article • American Journal of Hematology, November 1999, Wiley

     Dr Emmanuel J Favaloro

793. 
     Mesenteric vein thrombosis secondary to combined protein C deficiency and double heterozygosity for factor V leiden and prothrombin G20210A

     Article • American Journal of Hematology, November 1999, Wiley

     Dr Emmanuel J Favaloro

794. 
     Mesenteric vein thrombosis secondary to combined protein C deficiency and double heterozygosity for factor V leiden and prothrombin G20210A

     Article • American Journal of Hematology, November 1999, Wiley

     Dr Emmanuel J Favaloro

795. 
     Laboratory Testing, Diagnosis, and Management of von Willebrand Disease: Current Practice in Australasia

     Article • American Journal of Clinical Pathology, November 1999, Oxford University Press (OUP)

     Dr Emmanuel J Favaloro

796. 
     Identification and characterization of a novel mutation in von Willebrand factor causing type 2B von Willebrand's disease

     Article • British Journal of Haematology, May 1999, Wiley

     Dr Emmanuel J Favaloro

797. 
     Clinical utility of anticardiolipin antibody assays: high inter-laboratory variation and limited consensus by participants of external quality assurance programs signals a cautious approach

     Article • Pathology, January 1999, Elsevier

     Dr Emmanuel J Favaloro

798. 
     Comparison of the effects of two low fat diets with different α-linolenic:linoleic acid ratios on coagulation and fibrinolysis

     Article • Atherosclerosis, January 1999, Elsevier

     Dr Emmanuel J Favaloro

799. 
     A Novel Factor V Null Mutation at Arg 506 Causes a False Positive Factor V Leiden Result

     Article • Thrombosis and Haemostasis, January 1999, Thieme Publishing Group

     Dr Emmanuel J Favaloro

800. 
     Laboratory Testing for von Willebrand’s Disease: An Assessment of Current Diagnostic Practice and Efficacy by Means of a Multi-laboratory Survey

     Article • Thrombosis and Haemostasis, January 1999, Thieme Publishing Group

     Dr Emmanuel J Favaloro

801. 
     Type 2B von Willebrand’s Disease and Angiodysplasia

     Article • Thrombosis and Haemostasis, January 1999, Thieme Publishing Group

     Dr Emmanuel J Favaloro

802. 
     Medical research in New South Wales 1993–1996 assessed by Medline publication capture

     Article • The Medical Journal of Australia, December 1998, Australasian Medical Publishing Co. Pty Ltd. (AMPCo)

     Dr Emmanuel J Favaloro

803. 
     A Simple, Whole Blood Method for Assessment of Platelet Function

     Article • Thrombosis Research, May 1998, Elsevier

     Dr Emmanuel J Favaloro

804. 
     Biliary fibronectin: Significant limitation as a diagnostic tool in malignant biliary obstruction

     Article • Gastroenterology, April 1998, Elsevier

     Dr Emmanuel J Favaloro

805. 
     Laboratory Assessment of von Willebrand Factor: Altered Interpretation of Laboratory Data, and Altered Diagnosis of von Willebrand's Disease

     Article • Clinical and Applied Thrombosis/Hemostasis, April 1997, SAGE Publications

     Dr Emmanuel J Favaloro

806. 
     The MDA-180 coagulation analyser: a laboratory evaluation

     Article • Pathology, January 1997, Elsevier

     Dr Emmanuel J Favaloro

807. 
     Laboratory assays for von Willebrand Factor: relative contribution to the diagnosis of von Willebrand’s disease

     Article • Pathology, January 1997, Elsevier

     Dr Emmanuel J Favaloro

808. 
     Laboratory assessment of von Willebrand factor: differential influence of prolonged ambient temperature specimen storage on assay results

     Article • Haemophilia, October 1996, Wiley

     Dr Emmanuel J Favaloro

809. 
     Cardiovascular Risk Factors and Dietary Plant Omega-3 Verus Omega-6 Fatty Acids

     Article • Journal of the American Dietetic Association, September 1996, Elsevier

     Dr Emmanuel J Favaloro

810. 
     MUTATIONS IN A SUBGROUP OF PATIENTS WITH MILD HAEMOPHILIA A AND A FAMILIAL DISCREPANCY BETWEEN THE ONE‐STAGE AND TWO‐STAGE FACTOR VIII:C METHODS

     Article • British Journal of Haematology, August 1996, Wiley

     Dr Emmanuel J Favaloro

811. 
     A survey of heparin monitoring in australasia

     Article • Pathology, January 1996, Elsevier

     Dr Emmanuel J Favaloro

812. 
     Aminopeptidase-N (CD13; gp 150): Contrasting patterns of enzymatic activity in blood from patients with myeloid or lymphoid leukemia

     Article • Leukemia Research, September 1995, Elsevier

     Dr Emmanuel J Favaloro

813. 
     Laboratory Assessment of von Willebrand Factor:Use of Different Assays Can Influence the Diagnosis of von Willebrand’s Disease, Dependent on Differing Sensitivity to Sample Preparation and Differential Recognition of High Molecular Weight VWF Forms

     Article • American Journal of Clinical Pathology, September 1995, Oxford University Press (OUP)

     Dr Emmanuel J Favaloro

814. 
     Attenuated platelet sensitivity to collagen in patients with neurofibromatosis type 1

     Article • British Journal of Haematology, March 1995, Wiley

     Dr Emmanuel J Favaloro

815. 
     von Willebrand's disease: Use of collagen binding assay provides potential improvement to laboratory monitoring of desmopressin (DDAVP) therapy

     Article • American Journal of Hematology, March 1994, Wiley

     Dr Emmanuel J Favaloro

816. 
     Differential expression of surface antigens on activated endothelium

     Article • Immunology and Cell Biology, December 1993, Wiley

     Dr Emmanuel J Favaloro

817. 
     The hepatobiliary disease marker serum alanine aminopeptidase predominantly comprises an isoform of the haematological myeloid differentiation antigen and leukaemia marker CD-13/gp150

     Article • Clinica Chimica Acta, October 1993, Elsevier

     Dr Emmanuel J Favaloro

818. 
     Acidified Chloroquine Treatment for the Removal of Class I HLA Antigens

     Article • Vox Sanguinis, July 1993, Wiley

     Dr Emmanuel J Favaloro

819. 
     Von willebrand's disease: laboratory investigation using an improved functional assay for von willebrand factor

     Article • Pathology, January 1993, Elsevier

     Dr Emmanuel J Favaloro

820. 
     Characterization of GMP-140 (P-selectin) as a circulating plasma protein.

     Article • Journal of Experimental Medicine, April 1992, Rockefeller University Press

     Dr Emmanuel J Favaloro

821. 
     Heparin - induced thrombocytopenia: laboratory investigation and confirmation of diagnosis

     Article • Pathology, January 1992, Elsevier

     Dr Emmanuel J Favaloro

822. 
     CD‐13 (‘gp150’; aminopeptidase‐N): Co‐expression on endothelial and haemopoietic cells with conservation of functional activity

     Article • Immunology and Cell Biology, August 1991, Wiley

     Dr Emmanuel J Favaloro

823. 
     Development of a simple collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between Type I and Type II, von Willebrand??s disease

     Article • Blood Coagulation & Fibrinolysis, April 1991, Wolters Kluwer Health

     Dr Emmanuel J Favaloro

824. 
     Co‐expression of haemopoietic antigens on vascular endothelial cells: a detailed phenotypic analysis

     Article • British Journal of Haematology, April 1990, Wiley

     Dr Emmanuel J Favaloro

825. 
     Endothelial Cells and Normal Circulating Haemopoietic Cells Share a Number of Surface Antigens

     Article • Thrombosis and Haemostasis, January 1989, Thieme Publishing Group

     Dr Emmanuel J Favaloro

826. 
     Further characterization of human myeloid antigens (gp160,95; gp150; gp67): investigation of epitopic heterogeneity and non‐haemopoietic distribution using panels of monoclonal antibodies belonging to CD‐11b, CD‐13 and CD‐33

     Article • British Journal of Haematology, June 1988, Wiley

     Dr Emmanuel J Favaloro

827. 
     Immunophenotype of clonogenic cells in myeloid leukaemia

     Article • Leukemia Research, January 1988, Elsevier

     Dr Emmanuel J Favaloro

828. 
     Further studies on the heterogeneity of antigens recognised by CD‐1 monoclonal antibodies: distribution of epitopes and analysis of serological binding patterns

     Article • Immunology and Cell Biology, December 1987, Wiley

     Dr Emmanuel J Favaloro

829. 
     Further studies on the heterogeneity of antigens recognised by CD‐1 monoclonal antibodies: distribution of epitopes and analysis of serological binding patterns

     Article • Immunology and Cell Biology, October 1987, Wiley

     Dr Emmanuel J Favaloro

830. 
     TRANSPLANTATION OF MONOCLONAL ANTIBODY‐PURGED AUTOLOGOUS BONE MARROW FOR TREATMENT OF POOR RISK COMMON ACUTE LYMPHOBLASTIC LEUKEMIA

     Article • Australian and New Zealand Journal of Medicine, June 1987, Wiley

     Dr Emmanuel J Favaloro

831. 
     Coexpression of p165 myeloid surface antigen and terminal deoxynucleotidyl transferase: A comparison of acute myeloid leukaemia and normal bone marrow cells

     Article • American Journal of Hematology, September 1986, Wiley

     Dr Emmanuel J Favaloro

832. 
     Standardization of monoclonal antibodies for use in autologous bone marrow transplantation for common acute lymphoblastic leukemia

     Article • Pathology, January 1986, Elsevier

     Dr Emmanuel J Favaloro

833. 
     Myeloid progenitor surface antigen identified by monoclonal antibody

     Article • British Journal of Haematology, September 1985, Wiley

     Dr Emmanuel J Favaloro

834. 
     Human myeloid differentiation antigens identified by monoclonal antibodies: expression on leukemic cells

     Article • Pathology, January 1985, Elsevier

     Dr Emmanuel J Favaloro

835. 
     The role of buffer anions and protons in secretion by the rabbit mandibular salivary gland.

     Article • The Journal of Physiology, January 1982, Wiley

     Dr Emmanuel J Favaloro